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Abstract 
 
Prion pathologies are a group of fatal neurodegenerative disorders that afflict mammalian 
species. In these diseases the cellular prion protein (PrPC) misfolds into a disease related 
form, known as prion (PrPSc). This misfolded protein is able to recruit and convert the 
physiological PrPC into pathogenic PrPSc that accumulates and leads to neuronal death. 
Synthetic infectious prions generated from recombinant source of PrP (recPrP) were 
created in the past few years with the aim of assessing if these preparations could mimic 
the behaviors of natural prions. Particularly, synthetic prions offer a great tool for studying 
both the basis of prion replication and the mechanism behind the evolution of prion strains. 
Indeed, recent evidence suggests that, despite the absence of nucleic acids, prions can 
adapt their conformation in response to changes in the context of replication. In this thesis, 
we have analyzed the stability of a synthetic prion isolate previously generated and named 
amyloid #4. In particular, amyloid #4 was either injected in wild-type mice or amplified by 
means of an innovative technique named Protein Misfolding Cyclic Amplfication (PMCA) 
which is able to mimic in vitro the process of prion conversion which occurs in vivo. 
Injection of raw amyloid failed to induce any disease while the injection of the PMCA 
amplified material induced severe prion pathology characterized by the presence of an 
uncommon PrPSc. When further passaged in wild-type animals such PrPSc was able to 
differentiate in two different isolates able to sustain different types of prion disease. These 
two isolates were finally assessed in PMCA and we observed the generation of an 
alternative conformation whose biophysical properties were different from those of both 
inocula, suggesting that the in vitro context of replication selectively amplified a third PrPSc 
isolate. Taken together these results indicate that our synthetic prion undergoes to 
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process of evolution (selection/adaptation) dictated by the environment of its replication 
(bioassays VS PMCA). 
Synthetic prions can be used for studying prion adaptation and selection. Since all 
the proposed pharmacological treatments failed to cure these pathologies, understanding 
these behaviors of prions is of fundamental importance to design effective therapies for 
these devastating disorders.    
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CHAPTER I 
 
Introduction 
1.1 Prion disorders in animals and humans  
Prion diseases, or Transmissible Spongiform Encephalopathies (TSEs), are a large group 
of neurodegenerative diseases that afflict mammalian species. They can be (i) sporadic, 
(ii) genetic or (iii) acquired by infection. Animal TSEs include scrapie in sheep, goats and 
mufflons [1], Transmissible Mink Encephalopathy in ranch-reared mink (TME) [2], Chronic 
Wasting Disease in deer (CWD)  [3], Bovine Spongiform Encephalopathy in cows (BSE) 
[4], Feline Spongiform Encephalopathy in domestic cats (FSE) [5], Exotic Ungulate 
Encephalopathy in exotic zoo ruminants (EUE) [6] and Camel Prion Disease in camels 
(CPD) [7]. Sporadic human prion disorders comprise: sporadic Creutzfeldt-Jakob disease 
(sCJD), Variably Protease-Sensitive Prionophaty (VPSPr) [8] and sporadic Fatal Insomnia 
(sFI). Genetic human prion disorders include Gerstmann-Sträussler-Scheinker (GSS) 
syndrome [9, 10] Fatal Familial Insomnia (FFI) [10] and familial CJD (fCJD) that are 
associated to genetic mutations (point mutations, insertional mutations, etc.) in the prion 
protein gene (PRNP) [11, 12]. Acquired forms of prion diseases comprise: kuru [13], 
iatrogenic CJD (iCJD) attributed to infection with prion contaminated surgical instruments 
or infected human derivatives  and variant CJD (vCJD) that is related to consumption of 
BSE-contaminated cattle products (See section “Natural prion transmission”). Sporadic 
CJD is the most represented type of these diseases (85-90% of all CJD cases) with an 
incidence of 1-1.5 cases per 1 million population per year [14]. All these pathologies are 
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caused by the conformational conversion of the prion protein (PrPC) into a pathological 
form, known as scrapie PrP (PrPSc), that acquire infectious properties. Table 1 
summarized these mammalian prion pathologies. 
Disease Host 
Scrapie Sheep, goats and mufflons 
Chronic Wasting Disease (CWD) Deer, mule, elk 
Transmissible Mink Encephalopathy (TME) Mink 
Bovine Spongiform Encephalopathy (BSE) Cattle 
Feline Spongiform Encephalopathy (FSE) Feline (Cats, Cheetah) 
Exotic Ungulate Encephalopathy (EUE) Exotic zoo ruminants (Bovidae family) 
Camel Prion Disease (CPD) Camel 
sporadic CJD (sCJD) and 
sporadic Familial Insomnia (sFI) 
Humans 
Variably Protease Sensitive Prionopahty 
(VPSPr) 
Humans 
Familial CJD (E200K, V210I) Humans 
Fatal Familial Insomnia (FFI) Humans 
Gerstmann-Sträussler-Scheinker syndrome 
(GSS) 
Humans 
Iatrogenic CJD (iCJD) Humans 
Variant CJD (vCJD) Humans 
 
Table 1. Prion diseases in animals and humans.  
 
1.2 Historical background on prion diseases: from prion discovery to the “protein 
only hypothesis” 
The first report of what now we know to be a prion disease dates back to 1732 in 
Lincolnshire after an outbreak of scrapie in British farms [15]. However, the real origin of 
scrapie still remains an open question. For almost one century the causes of this animal 
disease lacked any explanation. In the late 1800s, Besnoit reported a hypothetical viral 
nature of the infectious agent behind these diseases. An important step in the story of 
prion discovery was taken in 1936 when two French veterinarians, Jean Cullie and Paul-
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Louis Chelle, tried to develop a vaccine against a common sheep virus (made of formalin 
fixed brain tissue from scrapie infected animals), and transmitted the scrapie disease to 
treated sheep. After this first accidental transmission, William Gordon (Moredun Institute in 
Edinburgh) tried to repeat the experiment by challenging 697 animals of which over 200 
developed scrapie pathology after 2 years [16]. After these pioneering experiments, the 
scrapie was then transmitted from sheep to mice by Roger J. Morris and Daniel Carleton 
Gajdusek [17] and from goats to mice by Richard Chandler [18] thus creating a multitude 
of prion strains adapted to common laboratory animal models (prevalently mice and 
hamsters) and permitted extensive studies on prion transmission that would have been 
almost impossible to test in sheep. After the discovery of the transmissibility of scrapie 
many hypotheses on the nature of the infectious agent able to induce this disease were 
proposed: (i) a self-replicating membrane [19, 20], (ii) a subvirus [20], (iii) a viroid and a 
spiroplasma or a retrovirus-like element [21] but none of these was unequivocally 
demonstrated. Another step towards the prion discovery were moved in 1957 when a 
young virologist and pediatrician, Daniel Carleton Gajdusek, moved to Papua New Guinea 
to investigate the cause of an unknown encephalitis-like pathology that afflicted the 
indigenous population [22]. Today we know that such pathology is a prion disorder, named 
kuru, horizontally transmitted in this population by cannibalistic rituals. The crucial event 
that provided the first correlation between scrapie and kuru came from an intuition of 
William Hadlow, a veterinarian and neuropathologist. He was invited to a conference 
where he saw microphotographs of brain tissue from kuru subjects and recognized strong 
similarities with the neuropathological alterations observed in scrapie pathology. 
Immediately, Hadlow sent a letter to Gajdusek proposing that the kuru and scrapie 
pathologies may be caused by the same infectious agent. After that episode, Gajdusek 
started experiments to test the transmissibility of kuru to primates. Under the supervision 
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of Dr. Clarence Joseph Gibbs, Gajdusek performed the first transmission of kuru to 
chimpanzees providing direct evidence of the infectious nature of this pathology [13]. 
However, because the long incubation period of the disease, the infectious agent was 
initially thought to be a slow virus [23]. Working on this unknown pathology, Tikvah Alper 
and colleagues in 1967 observed that the infectious agent associated to scrapie appeared 
uncommonly resistant to UV treatment and ionizing radiation [24]. In the same study, the 
authors reported the minimum molecular weight necessary for the infectivity being at 
around 2x105 Da thus ruling out the hypothesis of viral or bacterial nature of this infectious 
agent. These findings supported the “virino” theory of Alan G. Dikinson and George 
Outram [25] suggesting that the agent of infection could be a small nucleic acid tightly 
packaged and protected from conventional denaturing agents by a protein-coat that 
preserves the integrity of the genetic material. In 1967 a mathematician, John S. Griffith, 
on the basis of experimental observations proposed for the first time an innovative model 
ascribing the pathological agent of prion disorder to a protein able to self-replicate in the 
body of the host [26]. This is the so called “protein only hypothesis” supported by Stanley 
B. Prusiner that provided a significant amount of experimental evidence showing that the 
infectious agent causing prion diseases was a protein [27]. The term “prions” was coined 
by Prusiner to indicate this novel proteinaceous infectious agent. He went on to win the 
Nobel prize in 1997 for his discovery of prions, a new biological principle of infection. 
Prusiner’s group, in 1982, purified for the first time the protease-resistant prion protein 
from infectious material [28] and described the dose dependent correlation between the 
amount of purified material and the infectivity of this agent. Particularly, his group 
discovered that the infectivity level of this protein could be reduced using (i) agent that 
altered or destroyed all the protein structure or (ii) antibodies against PrP [29]. These data 
further supported the protein only hypothesis and unequivocally linked this infectious 
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protein to prion diseases. In 1985, Bruce Chesebro and colleagues identified the gene that 
encoding for prion protein (PRNP) [30]. Structural studies on the physiological cellular 
prion protein (PrPC) and the pathological related scrapie prion protein (PrPSc) demonstrate 
that these two proteins have the same chemical properties [31] and suggest that the origin 
of the infectivity seems to be dictated by a conformational rearrangement of PrPC induced 
by PrPSc trough a conversion mechanism. Another important study that reinforces the 
“protein only hypothesis” was the discovery of the direct association between mutation on 
the PRNP gene and familial forms of prion disease. The first genetic prion disease 
described in humans was the Gerstmann-Sträussler-Scheinker (GSS) syndrome 
characterized by a point mutation (P102L) in the PRNP gene [32]. Further studies revealed 
several mutations (point mutations or insertions) of the PRNP gene that are associated 
with different familial forms of prion disorders [33]. Finally, in 1993, Charles Weissmann 
developed a transgenic mouse model devoid of PrP and demonstrated that these mice 
were resistant to prion infection [34]. This observation provided an important step forward 
indicating that PrPC is necessary to sustain prion pathologies.   
 
1.3 PrPC 
1.3.1 Structure of PrPC 
PrPC is a glycophosphatidylinositol-anchored glycoprotein encoded by the PRNP gene 
located on chromosome 20 in humans and chromosome 2 in mice [35]. The PRNP gene, 
depending on the species considered, contains either 2 or 3 exons with the entire coding 
region being contained in the last exon thus excluding possible alternative splicing [36]. 
The PrPC is composed by two major domains: (1) the N-terminal unstructured domain and 
the (2) C-terminal structured domain. The N-terminal unstructured domain possesses 
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distinctive sequences identified as octarepeats with a consensus sequence of 
PHGGGWGQ that contains histidine residues able to bind monovalent and divalent 
cations (e.g. Cu+ and Cu2+). The octarepeat region of PrP binds Cu2+ with different modls 
of ion coordination [37]. The C-terminal structured domain is composed of two short 
antiparallel β-sheet strands (β1 and β2) and three α-helices (α1, α2 and α3) which provide 
a compact conformation conserved in all mammalian species (Fig. 1.1).  
 
Fig. 1.1 Schematic representation of PrPC structure. The protein structure is constituted by two different 
domains, the structured C-terminus domain and the unstructured N-terminus domain. The C-terminus is 
composed by three α helices indicated as α1, α2 and α3 and two β sheet strands named β1 and β2. Two 
glycosylation sites at Asn181 and Asn197 and a disulfide bond are present in the C-terminus domain. (From 
Biasini et al., Trends Neurosci 2012) 
 
Recently, a third beta sheet strand (named β0) (Fig 1.2) has been described [38].  
 
 
Fig. 1.2 Structure of the cellular prion protein (PrPC). Tridimensional structure of PrPC showed the 
compact conformation of C-terminus domain. The third β sheet strand recently identified is indicated as β0 
(yellow strand). The N-terminal domain is unstructured and possess octapeptide repeats that contain 
hystidine residues (in blue) able to bind divalent cations (orange dots). (from Legname, PLoS Path 2017) 
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PrPC is synthesized in the rough endoplasmic reticulum (ER) [35, 39] where it undergoes 
three main modifications: (1) addition of a GPI anchor, (2) formation of a disulfide bond 
between Cys179 and Cys214 [35, 40] and (3) N-linked glycosylation at Asn181 and 
Asn197 [41, 42]. Subsequently, the protein is directed to the Golgi network and the 
oligosaccaride chains are modified to produce complex-type chains with sialic acids [43]. 
Mature PrPC is composed of 208 amino acids and comprises three major forms differing in 
their glycosylation degree (referred as glycoform ratio): a di-glycosylated one (containing 
two glycan chains), a mono-glycosylated one (containing one glycan chain) and an un-
glycosylated form (lacking glycan chains) that confers to the protein different molecular 
weights [41, 43-45] (Fig. 1.3). Proteolytic processing was also described as post-
translation modification of PrPC. Particularly, one of the sites is located in the central 
region of the protein and produces the N-terminal N1 soluble fragment and the GPI-
anchored C-terminal C1 fragment [46] but PrPC may also be present as soluble full-length. 
                  
Fig. 1.3 Typical western blot pattern of PrPC. After electrophoretic fractionation and immunoblot, three 
bands of PrPC protein can be appreciated. The di-glycosylated form prevails on the mono- and un-
glycosylated ones.  
 
1.3.2 Functions of PrPC   
The biological functions of PrPC are not completely understood, yet it appears that PrPC is 
involved in different cell functions. Moreover, PrPC is involved with the synaptic activity 
36kDa
26kDa
PrPC
Di-glycosylated
Mono-glycosylated
Un-glycosylated
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[47], neurite elongation and synapse development [48, 49], metal metabolism [37, 50, 51], 
anti-apoptotic processes [52] and cell protection from oxidative stress [53, 54]. PrPC is also 
involved in cognitive and behavioral function such as long-term memory formation 
particularly for language development [55, 56] and the regulation of the circadian clock 
[57]. It is highly expressed in neurons and astrocytes and is concentrated in the synapses 
[58]. Moreover, one of the most fascinating aspects of PrPC functions is the involvement in 
cell signaling. The mechanism of signal transduction cannot be mediated directly by PrPC 
because it is a GPI anchored protein that can not interact with proteins of the cytosolic 
compartment but can instead interact with other transmembrane proteins and participate in 
signal transduction. The first evidence of these interactions was reported by Mouillet-
Richard and colleagues that described the caveolin-1-dependent coupling of PrPC to the 
proto-oncogene tyrosine-protein kinase Fyn (Fyn) that plays a role in the maturation of 
neuroectodermal progenitor mouse cell line (C11 cells) [59]. After this first report other 
membrane proteins were described as PrPC interactors, including (i) a protein involved in 
the neurogenesis, the neural cell adhesion molecule (NCAM) [60] (ii) laminin precursor 
receptor (LPR) [61] (iii) the N-methyl-D-aspartate (NMDA) receptor [62-64] (iv) the a7 
nicotinic acetylcholine receptor [65] and (v) the metabotropic glutammate receptor mGluR1 
[66].  
 
1.4 PrPSc 
1.4.1 PrPC can convert to PrPSc and acquire new biochemical features 
The PrPSc prions are the infectious agent behind the animal and human prion disorders. 
This protein arises from the conformational conversion of PrPC, but contrarily to this latter, 
PrPSc is rich in β-sheet structures, it is insoluble in mild detergents, partially resistant to 
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denaturation with chaotropic agents and is partially resistant to proteolytic digestion with 
proteinase K (PK). This specific resistance against PK digestion is commonly used for 
discriminating the PrPSc from PrPC. After PK treatment, PrPC is completely digested and 
the signal is undetectable at western blot (Fig. 1.4A). By contrast, PK treatment removes 
the N-terminal portion of the PrPSc while leaving the C-terminal fragment of the protein 
which is enriched in β-sheet structures. This form of PrPSc, named PrP 27–30, has lower 
molecular weight than the un-glycosylated one and maintains the three glycosylated bands 
(i.e. with two, one or without glycosylation) (Fig.1.4B). The ratio between these three 
isoforms enables the classification of different PrPSc conformation.  
 
Fig 1.4. Western blot analysis of PrPC and PrPSc. PK digestion completely remove the signal of PrPC ((A),  
(-) line without PK and (+) line with  PK) while the PrPSc was partially digested and the C-terminal fragment 
can be detectable and maintained the three band of the different isoforms of the protein (B).  
 
Misfolded PrPSc is infectious [28] and has a strong tendency to polymerize and form 
amyloid aggregates which accumulate in the brain [67]. The discovery of these structures 
had been originally described by Mertz and colleagues [68] that identified “rod-shaped” 
particles in fraction enriched for scrapie infectivity. Notably, large PrP amyloid fibrils are 
not required for infectivity as demonstrated by Caughey and colleagues in 2005 [69] that 
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described nonfibrillar particles with masses equivalent to 14-28 PrP molecules as the most 
efficient initiators of prion diseases. The accumulation of PrPSc amyloids in focal deposits, 
named “amyloid plaques”, can be detected on brain sections with specific amyloid dyes 
like Congo-red or thioflavin-S.  
 
1.4.2 Structure of PrPSc 
While PrPC structure is well reported, high-resolution structural determination of PrPSc is 
hard to solve due to its intrinsically insolubility and high propensity to aggregate. Defining 
the structure of the infectious conformers is essential for understanding the basis of prion 
replication and design structural-based therapeutic approaches. X-ray fiber diffraction [70, 
71], Cryo-electron microscopy [72] and indirect structural studies proposed the structure of 
PrP monomer within PrPSc particles as four-rung β-solenoid that provides molecular 
framework for the autocatalytic mechanism for propagation that gives rise to the alternative 
conformation of PrPSc (Fig. 1.5). Recent evidence suggests these different conformations 
provide to PrPSc different pathological characteristics [73, 74]. A β-solenoid structure is 
defined as a protein domain composed by regular secondary β-strands elements and can 
be classified by structural characteristics of (i) handedness, (ii) twist, (iii) oligomerization 
state, (iv) coil shape and (v) number of chains that wind around a common axis [75].  
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Fig 1.5. View of the possible ß-sheet stacking in a four-rung ß-solenoid structure of GPI-anchorless 
PrP 27–30. Characteristic distances of the four-rung ß-solenoid architecture are indicated. (from Vázquez-
Fernández E et al., PloS Path 2016) 
 
One of the most important advantages of cryo-EM technique is the preservation of the 
native structure of the specimens analyzed and gives more realistic measurements than 
other techniques. The proposed structure [72] is based on the study of prion amyloids 
purified from transgenic mice expressing GPI-anchorless PrP 27–30 (tg44). Cryo-EM 
analysis determined the average fibril segments constituted by repeating unit of 19.1 Å. 
This measurement is in agreement with ß-solenoid architecture that is expected to have a 
height of 19.2 Å (4 spaces of 4.8 Å between individual β-strands). After 3D reconstructions 
of these fibrils, the data collected revealed two distinct protofilaments, and, together with a 
molecular volume of 18,990 Å3, predicted the average height of each PrP 27–30 molecule 
as ~17.7 Å. This single particle analysis proposes an assembly unit along the fibril axis of 
20 and 40 Å might be composed by two PrPSc monomers configured in head-to-head 
arrangement. (Fig. 1.6). Another possible organization of these units is the head-to-tail that 
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gives rise to polar fibrils structure but the ~40 Å signal obtained [72] would favor the head-
to-head model. (Fig. 1.6) 
 
Fig 1.6. Schematic representation of head-to-tail or head-to-head possible architecture of PrPSc 
amyloid fibrils. (from Wille H et al., Pathogens 2018) 
 
All these observations were in agreement with previous X-ray fiber diffraction results and 
provided clear evidence that the structure of the core of PrPSc contains a four-rung β-
solenoid fold [76]. The high compact nature of β-solenoid core is also congruent with the 
PK resistance of C-terminal core of PrP (PrP27-30) while the unstructured N-terminal 
residues were easily digested. On the other hand, it has been observed also the presence 
of smaller PK-resistant fragments besides PrP27-30 [77, 78] in “atypical” PrPSc 
conformations. Particularly, many of these conformations are cleaved by PK at a position 
around 150-153 Amino Acids (AA) of PrP [79] that suggest the presence of an important 
loop that expose residues for PK cleavages also in the C-terminal domain of the PrP [79-
81].  
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1.4.3 Propagation mechanism of PrPSc 
The key pathogenic feature of PrPSc consists in the ability to transmit its misfolding to the 
normal PrPC through a mechanism still poorly understood. Two different models have 
been proposed: (i) the template assisted model and (ii) the nucleation-polymerization 
model.  
The template assisted model (or refolding model) assume that the conversion of 
PrPC and PrPSc is prevented by a high-energy barrier. The interaction with exogenously 
introduced PrPSc and PrPC induce the conformational conversion in a further PrPSc. This 
model implies the formation of heterodimeric PrPC-PrPSc unit that would initiate the 
conformational change of PrPC and became an homodimeric PrPSc-PrPSc. This latter might 
interact with other homodimer and eventually form larger aggregates. The rate-limiting 
state in this model is represented by the dimerization between PrPC and PrPSc monomers. 
 The nucleation-polymerization model (or seeding model) proposes that PrPC and 
PrPSc are in a reversible thermodynamic equilibrium. PrPSc represent a minor and transient 
isoform and might be stabilized only when forming highly ordered structures, referred as 
nuclei or seeds. In such seeds, PrPSc becomes stabilized and further PrPSc can be 
recruited and eventually aggregate to amyloid structures. Fragmentation of PrPSc 
aggregates increases the number of the nuclei that can recruit further PrPSc molecules and 
results in the replication of the agent.  The rate-limiting step of this model is the formation 
of the stable PrPSc nucleus. This step reflects the lag phase of spontaneous conversion 
and it is accelerated by adding preformed PrPSc seeds.  
A schematic representation of these models is reported in Fig. 1.7.  
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Fig. 1.7 Schematic representation of the models for prion propagation. The template assisted model (or 
refolding model) (A) and the nucleation-polymerization model (or seeding model) (B). (from Aguzzi et. al., 
Nat Rev Mol Cell Biol. 2001)  
 
These two models are not mutually exclusive and might represent different stages of PrPSc 
propagation. In fact, the initial seed could be produced by nucleation-polymerization 
process while the template assisted model might be involved in the elongation of the fibrils. 
In both models, the ∆G energy of the oligomeric or amyloid structures of PrPSc is lower 
than the energy of the native folding of the PrPC, and this shift thermodynamically favor 
this conversion in an exponential way (Fig. 1.8).    
 
 
Fig. 1.8 Free energy profile for the conversion of PrPC (referred as α-rPrP, circle) into PrPSc (referred 
as β-rPrP, triangle). This diagram highlights the slightly higher free-energy of PrPC with respect to misfolded 
PrPSc while PrPSc amyloids (triangles) displayed lower free-energy of both isoforms. The U and U’ represent 
the unfolded state of the protein. (modified from Silva et al., Cell 2008) 
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tain informational nucleic acids — in that they are
self-perpetuating and heritable7.
Eighteen years after Stanley Prusiner formulated
his PRION-ONLY HYPOTHESIS (FIG. 2) — for which he was
awarded the Nobel Prize in 1997 — there is still uncer-
tainty as to whether these two definitions coincide in
the case of mammalian prions, as it has not yet been
unequivocally established that the disease-associated
protein isolated by Prusiner and termed PRPSC represents
the infectious agent. Another problem is that, although
all AMYLOID PROTEINS and their precursors would fit the
second definition, these proteins do not seem to be
transmissible or infectious in vivo or in cell culture.
Although several yeast proteins have been shown to
fulfil both of these criteria (BOX 1), no such successes
have been reported for mammalian prions.
What is a prion?
The normal mammalian prion protein is known as PRPC.
In vitro conversion of this protein can yield a moiety
that has many of the physico-chemical properties that
are characteristic of PrPSc, the disease-associated prion
protein. These include aggregation into higher-order
quasi-crystalline complexes that are birefringent when
observed under polarized light (especially when stained
with amyloid dyes such as Congo red), formation of fib-
rils that are identifiable by electron microscopy and par-
tial resistance to proteolytic enzymes, as identified by
digestion with proteinase K8–10.
The crucial element that is common to the two defi-
nitions mentioned above, and that is absolutely required
for the classification of a protein as a prion, is transmis-
sibility. None of the experimental procedures reported
so far has unambiguously accomplished transformation
of the cellular prion protein PrPC into a transmissible
agent. Speculations abound as to why this has not been
possible: the requirement for additional cellular factors
distinct from PrPC, for example, has been invoked on the
basis of genetic evidence11, but has never been proved.
Universal consensus about the nature of the agent will
predictably be reached only once a synthetic reconstitu-
tion has been done from non-infectious material.
How the prion damages its host
Notwithstanding all the unresolved problems, certain
properties of the infectious agent can be studied.
Perhaps the most obvious question is this: how do pri-
ons damage the central nervous system, which is the
only compartment of the body that undergoes
histopathologically (FIG. 3) and clinically detectable
degeneration in prion diseases?
Cellular models of prion disease might be useful to
address this question, although prions replicate ineffi-
ciently in most established cell lines. Many studies have
been done using a synthetic peptide from the central
region of the PrPC molecule, which spontaneously
assembles into amyloid-like structures. In vitro, this
peptide can elicit reactions that resemble those seen in
brain cells during the late stages of prion disease. These
include activation of microglial cells, stimulation of the
production of intermediate filaments by astrocytes,
and even the death of neurons, all of which seem to
depend on the presence of the normal prion protein in
target cells12,13. But all of these studies suffer from a
fundamental problem. It is not clear whether the phe-
nomenon observed in conjunction with exposure of
cells to this small, amyloidogenic peptide bear much
relevance to what is happening in vivo during prion
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Figure 2 | The ‘protein-only’ hypothesis and two popular models for the
conformational conversion of PrPC into PrPSc. a | The ‘refolding’ or template-assistance
model postulates an interaction between exogenously introduced PrPSc and endogenous PrPC,
which is induced to transform itself into further PrPSc. A high-energy b rrier might prevent
spontaneous conversion of PrPC into PrPSc. b | The ‘seeding’ or nucleation–polymerization
model proposes that PrPC and PrPSc are in a reversible thermodynamic equilibrium. Only if
several monomeric PrPSc molecules are mounted into a highly ordered seed can further
monomeric PrPSc be recruited and eventually aggregate to amyloid. Within such a crystal-like
seed, PrPSc becomes stabilized. Fragmentation of PrPSc aggregates increases the number of
nuclei, which can recruit further PrPSc and thus results in apparent replication of the agent. In
sporadic prion disease, fluctuations in local PrPC concentration might — exceedingly rarely —
trigger spontaneous seeding and self-propagating prion replication.
Figure 1 | Confirmed cases of BSE plotted by month and year of onset. Data valid to end
of January 2000 (produced in June 2000). The good news is that the epizootic has been
receding since 1992. The not-so-good news is that, despite several predictions, the incidence
has not reached zero, and seems to be levelling off asymptotically at a low, but measurable,
height. (Source: British Ministry of Agriculture, Fisheries and Food.)
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Recent findings about the PrPSc structure enable the formulation of structural-based 
hypothesis on how PrPSc prions propagate [82]. The β-solenoid structure has native 
templating capabilities through the upper- and lowermost rungs that contain “unpaired” β-
strands that can transmit their hydrogen-bonding pattern into any amyloidogenic protein by 
direct contact [83]. The proteins that contain β-solenoid have evolved to be capped by 
loops or α-helices that protect the external edge of the protein from uncontrolled β-sheet 
propagation. Supporting this observation, the elimination of this edge capping by protein 
engineering produces unstable peptides that undergo to edge-to-edge-driven 
oligomerization [84]. Accordingly, the proposed β-solenoid structure of PrPSc can template 
an incoming unfolded PrP protein into an additional β-solenoid structure and produce a 
fresh “sticky” surface that sustain the templating propagation mechanism [85] (Fig. 1.9).  
 
 
Fig 1.9. Possible mechanism of PrPSc templating mechanism. In this schematic representation were 
reported the head-to-tail mechanism of PrPSc templating. The unfolded PrP protein interacts with the 
uncapped β-solenoid edge of the PrPSc dimer and adopts β-strand conformation by forming backbone 
hydrogen-bonds (indicated with red arrows). Once all the rungs have been templated (green, blue), the new 
molecule of PrPSc provide “fresh” templating surface for other PrP proteins. (from Wille H at al. Pathogens 
2018) 
 
In this model, it’s important to take into account that the large carbohydrate chains 
attached to PrP peptide probably impose constraints to this templating process. However, 
two possible mechanisms were proposed for this interaction: the head-to-head or head-to-
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tail interaction. At the moment, considering structural data collected from cryo-EM 
experiments [82] the head-to-head model appears to slightly favor the head-to-tail 
mechanism but the evidence is not strong enough to resolve this point [85]. By these 
mechanisms, PrPSc is able to accumulate in brain tissues of infected hosts and, with other 
neuropathological changes, represent the characteristic hallmark of prion pathologies. 
 
1.5 Common pathological features of prion diseases  
The common neuropathological characteristics of prion diseases comprise: (i) spongiform 
changes of the gray matter, (ii) reactive astrocytosis and microglial proliferation, (iii) 
neuronal loss and (iv) accumulation of PrPSc [86]. 
1.5.1. Spongiform changes 
Spongiform degeneration of the brain tissue is the pathognomonic lesion of prion 
disorders. It is characterized by numerous rounded vacuoles in the gray matter with a 
diameter from 2 to 20 μm. Microvacuolar spongiform change made of small vacuoles or 
confluent large coalescent vacuoles can be formed. These degenerations give the typical 
spongiform-like appearance of the brain tissue (Fig. 1.10).  
 
Fig 1.10. Hematoxylin and eosin stained sections of brain tissue. Normal brain tissue (A) and prion 
affected brain tissue (B). Arrows indicates the vacuoles typical of spongiform alteration.  
A B
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1.5.2. PrPSc accumulation and detection 
The deposition of the disease-associated protein PrPSc is the main neuropathological 
hallmark of these diseases. PrPSc deposition can be (i) synaptic, (ii) perivacuolar, (iii) 
perineuronal and (iv) in plaque (Fig. 1.11) but these patterns may overlap in the same 
affected brain [87]. Focal PrPSc accumulation can be divided in: plaque-like deposits (that 
are negative for specific amyloid staining) and amyloid plaques (that are detected by 
thioflavin-S or Congo Red). The distribution of PrP deposits and the spongiform 
degeneration do not always correlate [88]. 
 
Fig 1.11. PrPSc deposition patterns. Different PrPSc distribution patterns can be appreciated by 
immunohistochemical staining (after PK-treatment) of human brain tissues with anti-PrP antibody. (from 
Budka et al., Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders (eds D. W. 
Dickson and R. O. Weller) 2011) 
 
PrPSc is able to accumulate in specific brain structures leading to typical patterns of 
deposition. This characteristic appears closely related to the conformation of PrPSc and 
produce specific signatures of accumulation of PrPSc in affected brains [89]. An example of 
this tropism for brain structures can be appreciated in human prion pathologies where 
distinct conformation of PrPSc accumulate in different brain regions (Fig. 1.12).  
Synaptic Perivacuolar Perineuronal Plaques
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Fig 1.12. Accumulation of different PrPSc conformations in human brains. Immunohistochemical 
staining of PK-resistant PrP in human brains of patients affected by prion pathology showed different 
accumulation of pathogenic PrPSc among brain regions.  
 
PrPSc can be detected post-mortem by (i) immunohistochemical examination of brain 
tissues and (ii) biochemical assays using brain homogenates. Histologically, PrPSc can be 
detected on fixed-brain slices after treatment with PK enzyme and immunodetection with 
anti-PrP antibodies. Since PrPC and PrPSc share the same amino acidic sequence, PK 
treatment is necessary for removing all the PrPC from the tissue and permitting the 
detection of the PK-resistant isoform of PrP. Biochemically, PrPSc can be easily detectable 
in brain tissues by means of Western blotting after enzymatic digestion with PK. This 
assay, supported by neuropathological examination, is routinely used as diagnostic tool for 
prion diseases.  
 
1.5.3. Gliosis 
Prion diseases are characterized by the presence of prominent gliosis involving the 
proliferation of microglia and neuroinflammation of microglia and astrocytes. Increased 
glial fibrillary acidic protein (GFAP) is a common marker for astrogliosis in prion diseases 
[90] that is closely associated with the accumulation of PrPSc. The role of reactive 
PrPSc conformation 1 PrPSc conformation 2
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astrocytes that can be deleterious for neuronal survival in prion disease is unclear and 
may stimulate neurodegeneration in this pathological context. Microglial activation appears 
at early stages of prion diseases, before both spongiform changes and neuronal loss [91] 
and might contribute to neurodegeneration. Moreover, the evidence that the distribution of 
microglial proliferation correlates with spongiform changes and astrogliosis suggests a 
close association between microglial activation and neurodegeneration induced by prions 
[92].  
 
1.6 PrPSc tissues distribution in human and animals  
The distribution of PrPSc in peripheral tissues of human and animal TSEs is extremely 
variable and depends on the type of prion disease but generally its accumulation lower 
than that of brain tissue.  
 
1.6.1 Animal TSEs PrPSc distribution 
- BSE: PrPSc is mainly confined to the Central Nervous System (CNS), spinal cord, 
spinal ganglia, retina, bone marrow, distal ileum [93-95], peripheral nerves [96, 97] 
and skeletal muscle [98]; 
- Scrapie: PrPSc was found in CNS, brainstem, palatine tonsils, ileum Peyer’s 
patches, spleen, adrenal gland, pancreas, heart, skin, urinary bladder, mammary 
glands, salivary gland [99], lung, liver, kidney, skeletal muscle [100], blood [101], 
milk [102], saliva [103] and oral cavity [104]; 
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- CWD: PrPSc was found in CNS, brainstem, retina, peripheral nerves, spleen, lymph 
nodes, tonsils, esophagus, rectum, skin, pancreas [105-107], nasal mucosa, saliva 
[108, 109], urine [109], feces [110] and blood [108];  
- TME: PrPSc was found in CNS, spleen, mesenteric and retropharyngeal lymph 
nodes, thymus, kidney, liver, intestine and salivary gland [111, 112]; 
- FSE: PrPSc was found in CNS, spinal cord, spinal ganglia, nerve of the tongue, 
sciatic nerve, optic nerve, enteric nervous system and adrenal gland [113]. 
 
1.6.2 Human TSEs PrPSc distribution 
As for animal TSEs, also in human TSEs the distribution of PrPSc depends on the type 
prion disease. In the most common human prion disease, the sporadic CJD (sCJD), the 
PrPSc was found in CNS, retina [114], optic nerve [115], spinal cord [116], peripheral 
nerves [117], blood [118], urine [119], CSF [120, 121], olfactory mucosa [122] and, in 
some cases, in spleen and muscle after concentration by sodium phosphotungstic acid 
(PTA) precipitation [123, 124]. In the variant CJD prion pathology (vCJD) the PrPSc is more 
diffuse in peripheral tissues than sCJD and was found in spleens, tonsils, lymph nodes, 
retina, pituitary gland, thymus, proximal optic nerve [125], appendix, skeletal muscle [124], 
ileum, adrenal gland, pancreas, blood [126, 127] and urine [128]. 
 
1.7 Transmissibility of prions 
1.7.1. Natural transmission of prions 
Despite the fact that prion diseases are not contagious by contact they are transmissible (i) 
per-orally and (ii) parenterally. A classical report of natural transmission of prions is the 
	
	
36	
BSE epidemic outbreak in the mid-eighties that lead to about 180,000 cases of animals 
infected caused by the feeding of scrapie-contaminated meal to cattle [129]. Scrapie 
spreading in sheep appears to propagate by oral route by infected goat milk consumption 
[130], through ingestion of prion-infected birth-related tissue (placenta) [131] or by 
contaminated environment with secretion (urine, feces, saliva) of infected animals [132]. 
Recently, CWD horizontal animal transmission was reported and appears to readily occur 
via may models like oral and nasal route by direct contact with infected urine, feces or 
saliva from animals in both clinical and pre-clinical stage of CWD infection [133]. Another 
evidence of prion transmissibility is the Kuru epidemic in the first half of 20th century in 
Papua New Guinea. The transmission of Kuru prions was caused by cannibalism 
associated with funeral rituals [134]. The zoonotic transmission of BSE to humans caused 
by the ingestion of BSE-contaminated foodstuff was responsible for the emergence of 
variant CJD (vCJD) [135]. Notably, horizontal transmission of vCJD by blood transfusion 
have been reported in 5 cases [136].  
 
1.7.2. Iatrogenic transmission of natural prions 
Almost 300 cases of iatrogenic prion transmission in humans were caused by medical 
interventions [137]. Most of them were due to (i) administration of cadaveric human growth 
hormone [138], (ii) transplantation of dura mater [139], (iii) corneal transplants [140], (iv) 
stereotactic EEG recording [141] and (v) use of contaminated surgical instruments [142]. 
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1.7.3 Experimental transmission of prions  
By taking advantage of their infectious properties, different PrPSc conformations were used 
to perform experimental infection of wild-type and transgenic animal models of the disease 
with the aim of (i) studying their molecular, biochemical, and infectious features and (ii) 
assessing the susceptibility to prion infection. The experimental transmission can be 
achieved by different routes including: intracerebral, intraocular, instraspinal, 
intraperitoneal [143], intravenous [144], subcutaneous, dental [145], oral [146], intranasal 
[147] or by aerosol [148]. However, the efficiency of all these transmissions depends on 
multiple variables including: (i) the route of infection (intracerebral infection is the most 
efficient) and (ii) the susceptibility of the host where the prion material was transmitted. 
One of the principal features of PrPSc is its ability to be transmissible to some host species 
and not others. Indeed, the transmission of prions occurred in more successful way within 
the same species and is much less efficient between different species. This phenomenon 
is known as “species barrier” and produces an extension of the incubation time or total 
resistance to the disease in inter-species infections [149].  
 
1.8 The concept of PrPSc strains and the species barrier 
1.8.1. Prion strains  
One of the most intriguing aspect of prion pathologies is the fact that the physiological 
PrPC can misfold in different conformations of PrPSc [150]. These conformations, referred 
to as “prion strains”, are able to induce unique clinical, neuropathological and biochemical 
alterations in animal and human hosts [151]. Indeed, in humans there were described at 
least six different strains of PrPSc responsible of distinct pathological phenotypes [152]. A 
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prion strain can be identified on the basis of: (i) the time between the inoculation and the 
manifestation of the pathological symptoms (incubation time) and the time between the 
inoculation and the terminal stage of the disease (survival time) [153], (ii) clinical signs, (iii) 
pattern of PrPSc deposition in the brain [154] and (iv) degree of spongiform alterations in 
specific brain areas [155] (Fig. 1.14). Biochemically, there are four main characteristics 
enabling prion strain classification (after PK digestion): (i) the electrophoretical mobility of 
the unglycosylated band (21kDa or 19kDa referred as Type1 or Type 2 respectively, Fig 
1.13B), (ii) the glycosylsation profile of PrP (glycoform ratio) [156] (Fig. 1.13A), (iii) the 
extent of protease digestion [157] and (iv) the resistance to denaturation using chaotropic 
agents (e.g. guanidine-hydrochloride) [158] (Fig. 1.14). After Peptide-N-glycosidase F 
(PNGase F) digestion which is able to cleave the asparagine-bound N-glycans, the 
glycosylation of PrP protein were completely removed and only one isoform was observed 
after Western blot analysis. This treatment permits the precise identification of the 
molecular weight of the un-glycosylated band corresponding to Type 1 (21kDa) or Type 2 
(19kDa) (Fig. 1.13B). 
 
Fig 1.13. Example of different PrPSc strains and PNGase experiment. PK digestion and Western blot 
analysis of different human prion strains. These PrPSc showed different electrophoretical mobility of the 
unglycosylated band (e.g. Strain 5: 19kDa (T1) or Strain 6: 21kDa (T2)) and distinctive glycosylation profile 
with predominance of one isoform over the others (e.g. Strain 1: di-glycosylated, Strain 6: mono-
glycosylated) (A). PNGase digestion which removes the glycosylation of PrPSc permit the precise 
identification of the molecular weight of the un-glycosylated isoform of PrP (B).    
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Different analytical approaches, including Fourier Transform Infrared Spectroscopy (FTIR), 
Atomic Force Microscopy (AFM) and Circular Dichroism (CD) demonstrated that the 
differences in prion strains are likely associated to specific conformations of PrPSc [159, 
160]. From the structural point of view, slight differences in the arrangement of β-strands 
and loops of PrPSc molecule were suggested as possible sources of structural variability 
giving rise to different strains of PrPSc [161]. Particularly, differences in the topography of 
the upper- or lower-most rung of the proposed β-solenoid structure of the PrPSc monomer 
might change the templating surface and permit the generation of specific conformational 
variants of PrPSc. These considerations were supported by two common behavior 
observed for prion strains: (i) the ability to transmit the disease in vivo and maintain the 
same characteristics among susceptible host [162] and (ii) the existence of a species 
barrier that partially hamper the infection between hosts with different PrPC amino acidic 
sequences [163].  
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Fig 1.14. Main biological and biochemical features used to distinguish different prion strains. 
Differences between prion strains can be identified on the basis of biological and biochemical features that 
include: (A) the incubation periods, (B) the clinical signs and (C) the distribution of spongiform lesion and 
PrPSc deposition (D) the electrophoretic mobility of PrPSc after PK treatment, (E) the glycosylation pattern of 
PrPSc and (F) its resistance to PK digestion and stability to chaotropic agent (GdnHCl) treatment. 
 
1.8.2. The species barrier  
A key characteristic of prions is their ability to infect a limited number of other species. This 
phenomenon, known as species barrier, is likely imposed by the amino acid sequence of 
host PrPC that may drive the PrPC-PrPSc interactions and permit or prevents prion 
propagation. In the structurally-based propagation model previously proposed in Fig. 1.9, 
the entire sequence of PrP seems involved in this mechanism and contributes with its own 
steric and amino acidic charge constraints. For these reasons, the sequence homology 
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between PrPSc and the host PrPC appear significantly involved in inter-species 
transmission of prion diseases [164-166] and has also been referred to as ‘sequence 
barrier’ [167]. Nevertheless, rare cases of natural transmission between different hosts 
were reported. It’s widely accepted that the consumption of BSE infected meat induce in 
humans a prion pathology named variant Creutzfeldt-Jakob disease (vCJD) [135, 168]. 
Biochemical studies demonstrated that the vCJD in humans and the BSE in cow arise 
from the same prion strain confirming the direct relationship between these two 
pathologies. [135, 169]. Intriguingly, BSE prion strain was able to cross the species barrier 
not only with humans but also with other animal hosts including exotic felines such as tiger 
and cheetah [170], non-human primates [171] and domestic cats [172]. In some cases, the 
same BSE prion strain was able to induce the generation of different host-specific prion 
strains with differences in clinical changes, neuropathological alterations and biochemical 
features of PrPSc [169]. Experimentally, the species barrier can be overcome by repetitive 
animal passages. If the species barrier is partially permissive to the transmission, the prion 
strain used as inoculum gradually adapts to the new host and acquires stable infectious 
properties after a number of passages depending on the characteristics of strain and 
animals. An example of this “crossing” experiment is the TME transmission to hamsters. 
The origin of TME was attributed to scrapie-infected foodstuff used to feed minks in UK 
farms, but studies of the etiology of this prion disorder are not conclusive [173]. The 
inoculation of TME in the Syrian Hamster gave rise to two different prion strains: the first 
one induced severe and rapid pathological alterations and hyperactivity in animals (Hyper, 
HY) while the second one induced slow disease progression and lethargy (Drowsy, DY) 
[174, 175]. Biochemical and histological analysis of CNS confirmed the presence of 
different neuropathological alteration likely associated with two different PrPSc 
conformations. Such PrPSc showed unique electrophoretical mobility, resistance to PK 
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digestion and stability against Guanidine Hydrochloride [160, 176, 177]. A proposed 
explanation for this phenomenon might be the fact that TME is not a pure strain but is 
instead composed by at least two pathological PrPSc conformations and only one prevails 
in mink [178]. When TME is injected in hamsters, two distinct PrPSc conformations arises 
highlighting the possibility that prions undergo to process of adaptation or selection 
according to changes in the environment of replication although lacking DNA or RNA 
[179].   
 
1.9 Darwinian evolution of prions 
When prions are successfully transmitted between different species the characteristics of 
the original PrPSc may adapt to the new host environment and result in the generation of a 
new prion strain or a multitude of them [180]. Particularly, after the inter-species 
transmission the new prion strain undergoes to a process of “selection/adaptation” 
accompanied with the reduction of the incubation time, increasing of attack rate, changes 
in neurotropism and PrPSc deposition pattern and changes in PrPSc biophysical properties 
[181]. With this observation it’s possible to speculate that the (i) sequence of host PrPC, (ii) 
species-specific cellular cofactors or (iii) species-specific PrPC glycosyl composition can 
play a pivotal role in prion transmission and adaptation [182]. However, these 
considerations suggest that the mechanism behind the species barrier and the 
phenomenon of prion adaptation might be influenced by different variables.  
Two main hypotheses were proposed as possible mechanism for the prion adaptation 
observed in animals: (i) the “cloud” hypothesis and the (ii) deformed templating model 
schematically represented in Fig. 1.15.  
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The cloud hypothesis, originally proposed by Charles Weissmann in 2010 [183], 
infers that prion strains are composed by a population of isolates with different abnormal 
conformations (conformational variants) due to spontaneous changing in PrPSc structure 
[183, 184].  Modifications of the replication environment allows the most efficient variant to 
become the predominant component of the population by replicating over the others [185]. 
This model is in agreement with the natural selection postulated by Charles Darwin in the 
“The Origin of Species” that described the evolution process of a population over the 
course of the generations that results in the survival of individuals whose features are most 
suitable for such environment leading to their perpetuation.  
The other mechanism proposed, the deformed templating [186], postulates that the 
templating process is imperfect and will sometimes result in generation of altered PrP 
conformations. This process can be enhanced by changes of the replication environment 
that actively contribute to the generation of PrPSc variants and impose an “evolutionary 
pressure” able to select the conformations that better fit in the new context of replication. 
Particularly, according to this model, when a PrPSc template is not compatible with (i) the 
new environment or (ii) the amino acidic sequence of host PrPC a range of new 
conformational variants of PrPSc are produced via deformed templating. In other words, 
this model postulate that one misfolded pattern can seed an alternative self-replicating 
state with a different folding pattern [187] and the variant that best fits with the new 
environment can emerge. The deformed templating does not exclude the “cloud” 
hypothesis but suggests a mechanism by which conformational variants of a “cloud” 
undergo structural modification in a new environment and gives rise to a new “cloud” of 
conformations.  
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Fig. 1.15 Schematic representation of proposed mechanism behind prion strain adaptation. The 
“cloud” hypothesis (A) infers that a prion isolate is composed by different conformational variants, more (red) 
or less (other colors) represented. The modification of the environment (from A to B) provides selective 
advantages to a specific conformation (green) that is able to efficiently replicate and lead to an adaptation of 
the prion population. The deformed templating mechanism (B) postulates that the PrPSc variants arises via 
numerous PrPSc-dependent trial-and-error events that de novo generates a conformation that fit better in the 
new environment and replace the original PrPSc. (modified from Makarava N. and Baskakov I.V., PloS Path 
2013) 
 
These models are sustained by experimental evidence that highlight the ability of 
prions to evolve and adapt to different environment of replication. According to the cloud 
hypothesis, the classical example of prions heterogeneity is the generation of a multitude 
of prion strains after the injection of a pool of scrapie-infected sheep brains in mouse 
models [180]. The biological cloning of prions provides some information regarding the 
composition of a prion strain. In this experimental procedure,	similar to principles used in 
classical virology, the mice are inoculated with a limiting dilution of prion isolates which 
consist of 100-10000 PrPSc particles (referred to uncloned prion strain). The transmission 
in vivo was repeated 2-3 times to the point in which a single prion strain appears to be 
present. The major limitation of this procedure is represented by the number of PrPSc 
particles necessary for the animal infections. Indeed, a limiting dilution of a prion isolate 
likely contains multiple prion variants that might generate, after biological cloning, prion 
Cloud 
hypothesis
Deformed 
templating
Replication
environment (A)
New replication 
environment (B)
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strains composed by different PrPSc conformations. However, this method might permit the 
isolation of a “cloned” prion strain that maintains stable pathological and biochemical 
characteristics after animal passages. For example, when an uncloned mouse-adapted 
prion strain derived from scrapie-infected sheep brains (22C) was inoculated in other mice 
with different genotypes the appearance of a new prion strain was observed (22H). Cloned 
22C prion strain was able to keep its characteristics through animal passages indicating 
that the uncloned 22C prion strain was composed of a mixture of different conformational 
variants [180]. Modifications of the replication environment (e.g. with drugs known to 
interfere with prion replication like quinacrine [188] or swainsonine [183]) lead to the 
selection of drug-resistant prion populations. Particularly, in animals treated with 
quinacrine there was a selection of a conformational variant different from that observed in 
the brains of untreated controls [189]. Also, the inter-species transmission of a prion strain 
may generate new prion strains. Transmission of cloned 139A prion strain (derived from 
scrapie) from mouse to hamster and back to mouse generates a new prion strain, the 
139H/M [190].  
In direct support of the deformed templating model, fibrillization experiment where 
mouse recombinant PrP was induced to aggregate with hamster amyloids generated fibrils 
with different folding state within individual amyloid. The folding pattern of hamster 
amyloids was not compatible with the amino acidic sequence of mouse PrP and hybrid 
mouse-hamster fibrils, with two distinct folding patterns, were produced [191].  
Experimentally, it’s difficult to prove that the multitude of PrPSc appeared upon 
environment changes can be caused by de novo generation of conformational variants or 
due to preexisting minor PrPSc structures in the original prion strain [192, 193]. These two 
models are not mutually exclusive and might represent different aspects of the prion 
adaptation/selection phenomenon. 
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1.10 In vitro amplification and detection of PrPSc 
In recent years, two innovative techniques for prions amplification and detection were 
developed: (i) the Protein Misfolding Cyclic Amplification (PMCA) that allows the 
amplification of PrPSc by mimicking in vitro the pathogenic replication of prions observed in 
vivo and (ii) the Real-time Quaking Induced Conversion (RT-QuIC) which consent the 
detection of trace-amount of PrPSc in biological samples.  
 
1.10.1 Protein Misfolding Cyclic Amplification 
Originally developed by Claudio Soto in 2001 [194] the Protein Misfolding Cyclic 
Amplification is an ultrasensitive technique able to sustain the phenomenon of prion 
replication in vitro but in an accelerated manner. Particularly, PMCA consists in cycles of 
incubation and sonication of samples that contain trace amount of PrPSc in presence of an 
excess of PrPC provided by brain homogenates (BH) of healthy animals (wild-type or 
transgenic). During the incubation phase, PrPSc induces the conversion and aggregation of 
PrPC substrate. The sonication phase is able to fragment the PrPSc aggregates in small 
polymers (referred as “seeds”) which are able to further convert new molecules of PrPC to 
PrPSc. These two phases are repeated in a cyclic manner (Fig. 1.16). At the end of the 
reaction an aliquot of amplified products is diluted in freshly prepared substrate and 
exposed to additional cycles of sonication and incubation (referred to as rounds of PMCA). 
Therefore, after several rounds, the amount of PrPSc increase exponentially to a level 
easily detectable with common biochemical assays (e.g. PK-digestion and Western blot 
analysis) (Fig. 1.16) [195, 196].  
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Fig. 1.16. Schematic representation of PMCA technique. PrPSc (red square) are added to the substrate 
(made of PrPC) (purple circles) and then subjected to cycles of sonication and incubation. Western blot 
analysis (right panel) revealed that after three rounds of PMCA is possible to detect trace amount of prions 
undetectable before PMCA. (from Moda F., Prog Mol Biol Transl Sci 2017) 
 
One of the most important features of PMCA lies in the fact that the amplified products 
seem to retain the biochemical and infectious features of the original PrPSc [197] and for 
this reason it represents a great tool for studying (i) the prion biology [198], (ii) the 
mechanism of prion transmission [199], (iii) the species barrier [200], (iv) the strain 
adaptation phenomena [201] and has been recently optimized for (v) diagnostic purposes 
[126, 128].  
 
1.10.2 Application of PMCA to study in vitro the species barrier and prion adaptation 
PMCA has been successfully used for amplifying a large variety of prion strains and the 
products maintained both infectivity [197, 202] and strain specificity [203]. For this reason 
PMCA can be applied to study the species barrier and the mechanism of prion adaptation. 
An example of PMCA application for these studies was reported by Green and coworkers 
in 2008 [203]. Using as substrate transgenic mice expressing cervid prion protein 
Tg(CerPrP), PMCA was able to replicate with high fidelity CWD prion strain. Using the 
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same method to amplify RML, PMCA demonstrate the ability to overcome the species 
barrier and produced a novel prion strain similarly to that observed in animal transmission 
experiments using Tg(CerPrP) mice. Notably, the abrogation of the transmission barrier in 
PMCA required much shorter period of time respect to classical animal transmission and 
enable the characterization of new prion strains that arose from inter-species transmission. 
Nevertheless, with PMCA it is possible to generate artificial new prion strains of species 
resistant to prion infection [204]. The ability of this technique to cross in vitro some 
transmission barriers by forcing the process of amplification and generating prion disorders 
in species assumed to be resistant to prion infection [204] might turn a disadvantage for 
studying this phenomenon and correlate the in vitro results with the natural mechanism of 
prion transmission. Another important aspect of prion biology that can be studied with 
PMCA technique is the adaptation of prions in response to changes of the replication 
context. Inter-species animal transmission of prions generated new strains with specific 
biochemical and neuropathological features that were able to change and adapt during 
animal passages and the same mechanism of adaptation can be studied also in vitro by 
PMCA. Indeed, as reported by Castilla and colleagues in 2008 [200], PMCA was 
successfully applied to overcome the large in vivo species barrier between hamsters and 
mice [190] and generate new prion strains. Particularly, RML mouse prion strain was 
added to normal hamster brain homogenate and subjected to PMCA. The amplified 
product composed by misfolded hamster PrPC was able to induce prion pathology in wild 
type hamsters. Similarly, 263K hamster prion strain was subjected to serial rounds of 
PMCA amplification using mouse brain homogenates and generated a PrPSc which was 
infectious when challenged in wild type mice. Notably, these two new prion strains 
possess different neuropathological and biochemical characteristics from RML mouse and 
263K hamster prion strains. Serial rounds of PMCA amplifications revealed a progressive 
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adaptation of the newly in vitro generated prion strains with a progressive change of the 
biochemical characteristics. These findings suggest that PMCA might mimic the 
mechanism of prion stabilization following inter-species transmission observed in in vivo 
but in an accelerated manner. In the same year, Meyerett and colleagues [201] described 
the amplification of D10 strain of CWD prions using serial PMCA (sPMCA) with transgenic 
mouse expressing cervid PrP (Tg(cerPrP)1536) brain homogenate as substrate. The 
resultant amplified products induced prion disease in CWD-susceptible Tg(cerPrP)1536 
mice with shorter incubation time respect to the D10 original strain, similarly to that 
observed in vivo with sub-passage of D10 inoculum. Notably, in vitro-amplified and animal-
passaged D10 produced brain lesion profile in animals, glycoform ratios and 
conformational stability profiles of PrPSc significantly different than those produced by the 
original D10 prion strain in Tg(cerPrP)1536 mice. These results highlighted another 
important aspect involved in prion adaptation, the effect of the biological environment 
where prion replicate. In vitro studies using PMCA may help in dissecting this aspect. As 
reported by Gonzales-Montalban N. and colleagues in 2013 [205], PMCA adaptation of 
263K and HY hamster prion strains to RNA-depleted substrate and then re-adapted by 
amplification in normal brain homogenate containing RNA resulted in a stable 
transformation of the biophysical characteristics, in terms of resistance to PK treatment 
and stability to chaotropic agents, of the original PrPSc. These results suggested that other 
than changes in PrP amino acidic sequence also modification of the environment of 
replication can play an active role in prion adaptation and selection. Another experimental 
evidence of the fundamental role of the environment in prion adaptation was recently 
reported by Katorcha E. and colleagues [206]. In their work, hamster 263K prion strain was 
propagated under normal and RNA-depleted conditions using seral PMCA amplification 
conduct first in mouse brain homogenate and then re-adapted with PMCA in normal 
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hamster substrate. The amplification in normal mouse brain homogenate and then in 
hamster substrate produced an amplified product able to induce a prion phenotype in 
hamsters comparable to the original 263K. Surprisingly, 263K amplified in RNA-depleted 
mouse substrate and then re-adapted by PMCA amplification with normal hamster brain 
homogenate generated a new disease phenotype when serially passaged in animals. 
Notably, 263K amplification in RNA-depleted mouse substrate and then in RNA-depleted 
hamster homogenate completely abolished its infectivity suggesting that RNAs might be 
important for assuring a high fidelity of prion replication. Taken together, these lines of 
experimental evidence suggest that PMCA technique offer a great tool for studying 
phenomenon of species barrier but also for mimicking the adaptation process after inter-
species transmission of prions in a faster manner and in well defined experimental 
conditions.  
 
1.10.3 Real-time Quaking Induced Conversion  
The RT-QuIC technique originally developed by Atarashi and colleagues in 2008 [207], is 
based on cycles of vigorous shaking and incubation in 96-well plates. Soluble recombinant 
prion protein (recPrP) is used as substrate for detecting trace amount of PrPSc (referred as 
seeds), resulting in formation of aggregates and amyloid structures. During incubation, 
PrPSc induce the conformational change of recPrP that aggregate and form large amyloid 
fibrils. These recPrP aggregates can be detected with fluorescence plate readers, using 
thioflavin-T (ThT) which binds amyloid structures. Thus, the increasing in fluorescence is 
proportional to the formation of the amyloids and was recorded in a real-time manner. The 
shaking phase promotes the fragmentation of the amyloid fibrils, forming more reactive 
seeds able to recruit more recPrP substrates and resulting in an exponential increase in 
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amyloid formation (Fig. 1.17). The parameters that affect the sensibility and specificity of 
the technique include: (i) truncation of recPrP substrates, (ii) temperature, (iii) shaking 
speed, (iv) shaking interval, (v) pH, and (vi) concentrations of detergent.  
 
Fig 1.17. Schematic representation of RT-QuIC technique. Trace amount of PrPSc (red square) are added 
to the substrate of recombinant PrP (recPrP, gray hexagons) with the addition of thioflavin-T amyloid 
fluorescent dye (ThT). PrPSc induce recPrP aggregation in amyloid structures that bind ThT. The shaking 
phase is able to brake the amyloid aggregates and create small seeds that are able to recruit other recPrP 
molecules during the incubation phase. The signal of ThT is recorded in real-time and proportionally 
correlate with the amount of amyloid structures. (from Moda F., Prog Mol Biol Transl Sci 2017) 
 
One of the most important aspects of RT-QuIC is the high sensitivity and specificity 
achieved for prion detection from different sources. This technique was optimized for the 
detection of different animal and human prion strains including sporadic and genetic 
human prion strains, classical and atypical scrapie in sheep, BSE in bovine, CWD in elk 
and deer and different hamster and mouse prion strains [208]. In this case, the “species 
barrier” appear overcome by the biochemical conditions for amyloid formation and the 
sequence homology between recombinant substrate and seed is not strictly required. 
Indeed, hamster recombinant PrP display high sensitivity and specificity to detect PrPSc 
derived from human infected samples and enable the detection of PrPSc in cerebrospinal 
fluid (CSF) or olfactory mucosa from patients with sCJD [121, 209, 210]. Recently, 
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recombinant PrP with Bank vole amino acidic sequence were described as “universal 
acceptor” of a multitude of prion strains from human and animal sources [208]. 
 
1.10.4 Application of RT-QuIC to study in vitro the species barrier and prion adaptation 
RT-QuIC assay can be used for studies the species barrier in highly pure system without 
the interference of cellular cofactors. However, using RT-QuIC the study of inter-species 
transmission is limited to the protein-protein interactions without the contribution of other 
environmental components that might significantly influence the species barrier. Recently, 
RT-QuIC was used to assess the impact of transmission to a new species of feline CWD 
(fCWD) and FSE prion strains [211]. This work suggested that, at the level of protein-
protein interaction, CWD is able to adapt to a new species more readily than does BSE 
and the barrier preventing transmission of CWD to humans may be less robust than 
estimated. However, all these studies are strongly influenced by the experimental settings 
(e.g. buffer composition, time of shaking and incubation) used for the RT-QuIC reactions. 
Indeed, similar study on the species barrier between humans and deer, but using different 
RT-QuIC experimental conditions, conducted to the opposite conclusion suggesting that 
CWD is not transmissible to humans [212].  
 
1.11 Synthetic prions can be generated in vitro 
One of the most fascinating aspects of prion research is the fact that, under specific 
biochemical conditions, bacterially-expressed recombinant prion protein (recPrP) can be 
misfolded in vitro thus acquiring infectious properties resembling those of natural prions 
[213, 214]. Synthetic prions can be used for studying different features of prions, including 
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the basis of their propagation properties and their capability to modify their conformation in 
different environments. The use of synthetic prions permits the study of different prion 
features in a highly pure system without the interference of other components which are 
instead present in the brain when studying natural prion transmission.   
 
1.11.1 Historical background on synthetic prions 
The first demonstration that in vitro generated synthetic prions could acquire infectious 
properties came from an important study published in 2000 by Kiotoshi Kaneko and 
collaborators [215]. Kaneko used in his work a transgenic mouse model expressing low 
levels of the mutant P101L PrP (Tg196), which spontaneously developed mild alterations 
in the CNS after more than 600 days [216]. These models were intracerebrally inoculated 
with a peptide (55 residues) of recombinant mouse PrP carrying the P101L mutation 
refolded into a β-sheet structure (that was named MoPrP(89-143,P101L)) or folded in 
different a conformation (without β-structures). Two hundred days post-injection, all mice 
injected with MoPrP(89-143,P101L) developed severe neuropathological changes typical 
of prion diseases, while the injection of the other conformation failed to induce any 
pathological alteration. Neuropathological and biochemical analysis revealed different 
characteristics with respect to these of typical RML mouse prion strain. Surprisingly, PrPSc 
accumulated in the brain was not PK resistant [217]. This uncommon PrPSc retained its 
infectious properties when transmitted to the same transgenic mice but the infectivity was 
lost when injected in wild-type animals [218]. After this first attempt to generate infectivity 
in vitro, several approaches to generate β-sheet rich conformation of misfolded 
recombinant PrP were explored. All these studies were aimed to address the question 
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whether PrPC alone is the necessary and sufficient molecule for the spontaneous 
formation of prions without the presence of any exogenous agent [219].  
 
1.11.2 Generation of synthetic infectious prions starting from recPrP 
In 2002, Ilia V. Baskakov and collaborators started to characterize the kinetic pathways of 
in vitro amyloid formation using bacterially-expressed recombinant mouse PrP 
corresponding to the PrP27-30 peptide (residues 89-231). In details, under specific 
biochemical conditions PrP27-30 acquired two different conformations: β-oligomers (in the 
presence of acidic pH and urea) and fibrillar structures (neutral pH and low concentration 
of urea), which possessed typical tinctorial properties of amyloid structures. The kinetic of 
the protein aggregation was measured in real-time manner with Thioflavin-T (ThT) [220]. 
An important discovery achieved in this work was the fact that the kinetic of amyloid 
formation could be considerably anticipated by the addition of pre-formed amyloid 
assemblies (seeds) with respect to the self-aggregation of the protein alone. This evidence 
showed for the first time that the formation of recombinant PrP fibrils can be promoted by 
seeding. This observation led to the development of the Amyloid Seeding Assay (ASA) 
[221] and, most recently, the RT-QuIC [207]. Then the infectivity of these fibrils was 
assessed with animal bioassays [213]. Particularly, transgenic mice (Tg9949) 
overexpressing (16-32 X) N-terminally truncated PrP (residues 89-231), were 
intracerebrally inoculated with (i) in vitro generated PrP amyloid fibrils (unseeded 
amyloids) and (ii) amyloids generated from recombinant PrP with the addition of pre-
formed amyloid aggregates (seeded amyloids). All mice injected developed prion disease. 
Notably, the first group exhibited longer incubation time (474 days post infection) than the 
second one (382 days post infection). Nevertheless, both groups were characterized by 
neuropathological changes (vacuolation profile and the presence of PK-resistant PrP) that 
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differ from known mouse prion strains. Biochemically, the brains of animals injected with 
seeded amyloid fibrils were characterized by more PK-resistant PrP than the other mice. 
The prion generated in the brains of Tg9949 mice inoculated with seeded amyloid fibrils 
was designated as MoSP1 and this new prion isolate was successfully passaged into wild-
type mice and acquired protease resistance. After the first synthetic prion experiment [213] 
different recombinant mouse PrP amyloid fibrils were produced by the same laboratory 
and challenged in vivo. Particularly, David Colby and coworkers were able to produce a 
subset of 11 PrP amyloids with different conformations. These different preparations were 
obtained by changing the biochemical and physical conditions used for their formation, 
including pH, chaotropic agent concentration (urea) and temperature [214]. The infectivity 
of these preparations was assessed in transgenic mice overexpressing (4-8 X) the wild-
type mouse prion protein (Tg4053). Ten out of eleven preparations caused disease with 
distinguishable patterns of neuropathological alterations and PrPSc deposition in the brain, 
suggesting that each preparation was able to induce a specific prion disease in these 
animals. This work indicates that recombinant amyloids generated with different 
conformations can induce diverse pathologies in susceptible hosts then linking the 
structures of the infectious amyloids with the phenotype of the disease (resembling the 
strain phenomenon observed with natural prions). 
The majority of the studies on synthetic prion infectivity were carried on transgenic 
mouse models overexpressing wild-type or mutated PrPC for increasing the susceptibility 
to the infection. However, another study [222] based on the generation of synthetic 
hamster prions demonstrated that wild-type hamsters are susceptible to synthetic prion 
infections and the use of genetically modified animals is not always required. Particularly, 
the β-sheet rich conformation produced with full-length hamster PrP under chaotropic 
conditions were subjected to “annealing” prior to inoculation. Basically, this procedure 
	
	
56	
consists of an incubation of the amyloids with hamster normal brain homogenate (NBH) 
and subjected to cycles of heating at 80°C followed by and incubation at 37°C for 5 times. 
The resulting homogenate was analyzed by Western blotting and a 16kDa PK-resistant 
band was detected. Amyloids annealed in bovine serum albumin (BSA) instead of brain 
homogenate failed to produce PK-resistant band. The same samples (NBH and BSA 
annealed fibrils) were intracerebrally inoculated in wild-type hamsters. The NBH-annealed 
preparation induced the accumulation of PrPSc but failed to induce clinical disease at the 
first passage. Only after serial transmissions, wild-type animals developed the disease. 
The lack of clinical symptoms in the first passage was ascribed to different factors: (i) the 
slow replication of PrPSc and (ii) the low titer of the infectious species presents in the 
inoculum (only a small subpopulation of fibrils may be infectious). Moreover, the 
differences between the structure of the host PrPC and recombinant amyloids may 
decrease the seeding activity and consequently extend the incubation time of the disease 
[223]. This newly generated prion isolate named SSLOW (Synthetic Strain Leading to 
OverWeight) produced a new type of prion disease characterized by (i) a very long 
incubation time, (ii) peculiar patterns of PrPSc deposition and (iii) specific neurotropism 
(lower involvement of the cerebellum). Notably, both NBH and BSA annealed preparation 
were able to induce prion disorder at second passage in wild-type animals and the PK-
resistant PrP showed identical band shift suggesting the possibility that the same prion 
isolate might emerge in serial passages from two different inocula. While the 
conformational stability of SSLOW appeared similar to that of 263K the differences in the 
incubation time of these two strains indicate that other factors than PrPSc stability can play 
an important role in prion replication mechanism. 
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1.11.3 Contribution of PMCA to generate and study synthetic prions  
Another strategy exploited to generate synthetic infectious prion is the PMCA, a technique 
developed by Claudio Soto’s group [194]. Using different sources of PrPC (recombinant, 
purified from animal brains or from total bran homogenates) PMCA demonstrates the 
ability to generate de novo infectious PrPSc in well defined in vitro conditions. In 2007, the 
group of Surachai Supattapone [224] showed that using a purified PrPC preparation from 
hamster brain homogenate, efficient PMCA propagation of infectious prions required the 
presence of polyanion molecules, such as nucleic acids, glycosaminoglycans, 
phospholipid-rich membranes and chaperone proteins suggesting their involvement in 
prion replication. Although polyanions may not be absolutely required to form an infectious 
prion, they may increase the efficiency of prion conversion or modify some biochemical 
properties of PrPSc [205]. Most notably, this work demonstrated that PrPSc could be 
spontaneously generated de novo in PMCA from these components in a stochastic 
manner. Remarkably, this preparation was able to produce prion pathology in wild-type 
hamsters. Different negatively charged macromolecules, in particular RNA [225], synthetic 
lipid in combination with purified RNA [226] or only synthetic lipids [227, 228] were 
reported to enhance PrPC conversion and promote the de novo generation of prion. In 
2013, Zhihong Zhang et al. [229] reported that after several rounds of PMCA amplification 
using recombinant mouse PrP two types of PK-resistant and self-perpetuating structures 
(recPrPres) were generated de novo. In particular, these structures were produced using 
recombinant prion protein, synthetic phospholipid 1-palmitoyl-2-oleoylphosphati-dylglycerol 
(POPG) and total RNA isolated from normal mouse liver. After several rounds of PMCA 
two recPrPres characterized by a PK-resistant core of 17KDa and 14KDa were generated 
(11 rounds for the 17kDa form and 5 rounds for 14kDa recPrPres). Only the 17kDa 
recPrPres was able to induce prion disease when injected in wild-type mice (CD1), with an 
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average survival time of about 172 days. In contrast, 14kDa recPrPres totally failed to 
induce any disease. Notably, second-round transmission in vivo confirmed the infectivity of 
17kDa recPrPres with an average survival time of about 161 days. The same group in 2012 
[230] demonstrated that infectious prions can be generated de novo by replacing the total 
liver RNA with a synthetic polyriboadenylic acid [poly(rA)]. The use of [poly(rA)] instead of 
mouse-derived RNA for the generation of infectious recPrPres exclude the possibility that 
RNA-like molecules or information contained in RNA sequence were necessary for in vitro 
conversion of PrPC in its infectious isoform.  
PMCA technique can be also used for generating de novo infectious PrPSc from 
normal brain homogenates. As reported by Barria and colleagues in 2009 [231], PMCA 
were able to generate de novo PrPSc using hamster and mouse brain homogenates. 
Precisely, in standard PMCA amplification (rounds of 144 cycles of incubation and 
sonication) the spontaneous formation of hamster and mouse PrPSc does not occur. The 
extension of the number of cycles per round (from 144 to 240 cycles) of PMCA induces the 
generation of PrPSc in both hamster and mouse brain homogenates (used as PMCA 
substrates) after 9 and 10 rounds, respectively. Notably, de novo hamster PrPSc was 
infectious in wild-type animals and produced a new disease phenotype. Taken together 
these findings demonstrate that this technique is an useful tool for studying the role of 
different cofactors to influence the generation of infectious synthetic prions.  
 
1.11.4 Autocatalytic propagation versus infectivity 
The protein-only hypothesis proposed that every PrP capable to replicate in an 
autocatalytic manner is infectious. However, not all synthetic prions able to self-replicate 
are infectious or the infectivity level is undetectable with common bioassays. In 2015, the 
group of Surachai Supattappone observed structural and functional differences between 
	
	
59	
infectious and non-infectious autocatalytic in vitro generated PrP conformers from recPrP 
[232]. Particularly, two distinct conformers were produced with or without the addition of 
cofactors. Amyloids produced with cofactor were infectious in wild type animals while the 
preparation without cofactors was not able to efficiently induce prion pathology. [227]. Both 
conformers are able to efficiently replicate in PMCA using recPrP as substrate but only the 
high infectious conformer (generated with cofactors) is able to convert in vitro the native 
PrPC from brain homogenate. Structural hydrogen/deuterium exchange mass spectrometry 
(DXMS) studies revealed similar solvent accessibility between these two conformers 
except for two domains (including AA 91-115 and 144-167) of the PK-resistant C-terminal 
core. Raman spectroscopy and immunoprecipitation experiments confirmed that these 
domains adopt distinct conformations between the high infectious and low infectious 
structures suggesting specific structural constrains required for the infectivity. Wang and 
colleagues in 2017 [233], generated different recPrP conformations using PMCA in 
presence of different concentration of mouse liver RNA as cofactor. Conformers generated 
with low concentrations of RNA were not infectious while structures generate with high 
concentrations of RNA were infectious in wild-type mice. The overall architecture of these 
conformation was similar but, despite their ability to efficiently replicate in vitro, slightly 
structural differences might govern the in vivo infectivity. These reports highlighted that the 
in vitro ability to self-replicate of recombinant prions does not necessary result in 
pathogenicity that is instead enciphered in fine structural arrangement of the infectious 
conformers.  
 
1.11.5 From recombinant amyloids to bona fide PrPSc  
The generation of synthetic prions from recombinant source of PrPC in vitro have provided 
the strongest proof for the protein-only hypothesis. However, these preparations generally 
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fail to induce prion pathology with high efficiency as expected, especially in wild-type 
animals. In fact, synthetic preparation display infectivity in transgenic animals with high 
expression of PrPC or wild type after relatively long incubation time, long silent clinical 
stage and with low efficiency. Two models might explain this behavior: the first (i) assumes 
that the amyloid fibrils preparation contains minute amount of PrPSc that needs long time 
and repetitive in vivo passages for replicating at a level sufficient to induce pathological 
alteration, the second (ii) infers that recombinant amyloid preparations does not contain 
PrPSc but are able to convert PrPC in atypical form of PrP that, after long silent stage, 
evolve in authentic PrPSc. These two models are schematically represented in Fig 1.18. 
 
 
 
Fig. 1.18 Schematic representation of two mechanisms responsible for generating transmissible 
prion diseases from recombinant amyloids. 
Two mechanisms were proposed for the generation of PrPSc from recombinant amyloids. According to the 
first mechanism (A) the amyloid fibrils preparation contains very small amounts of PrPSc (triangles). The 
silent stage of the disease among in vivo passages is attributed to the long time required for amplification of 
PrPSc at sufficient levels to induce the pathology. A second mechanism (B) referred to as deformed 
templating postulates that there are no PrPSc particles in the preparations of amyloid fibrils. When inoculated 
into animals, amyloid fibrils can convert PrPC into an atypical form of PrP named atypical PrPres. Atypical 
PrPres undergoes slow transformation, a process that might require long silent stage, before authentic PrPSc 
emerges after repetitive passages. (from Makarava et al., PlosPath 2011) 
 
The classical templating mechanism postulates that PrPSc induce the conformational 
conversion of PrPC and transmit its misfolding with high fidelity. However, experimental 
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evidence highlights that the structure of recombinant amyloids used for inoculation and the 
infectious PrPSc detected in animals appear very different [76, 234] suggesting that the 
transition between these two structures might involve several steps. A mechanism 
involving two steps was proposed for explaining this phenomenon [235]. As a first step, 
synthetic prion fibrils induced PrPC misfolding in alternative self-replicating state, referred 
as atypical PrPres. This mechanism is supported by the fact that atypical PrPres 
characterized by short C-terminal PK resistant core was detected in hamsters injected with 
synthetic amyloid [236]. At this stage, atypical PrPres is able to replicate without causing 
disease. Particularly, atypical PrPres preferred mono-glycosylated PrPC as substrate and its 
amplification is RNA-independent. During the second step the authentic PrPSc were 
formed via rare and stochastic deformed templating events (See section Darwinian 
evolution of prions) as reported in the schematic representation in Fig. 1.19.  
 
Fig. 1.19 Schematic representation of the PrPSc genesis from rPrP synthetic fibrils. 
This model is composed by two steps: in the first rPrP trigger the formation of an atypical PrPres that 
replicates silently without causing clinical disease. The replication of atypical PrPres occasionally produces 
PrPSc (second step) that replicates faster than the atypical isoform. For synthetic hamster prion strains, both 
forms of PrP can be detectable after PK treatment with antibodies that recognize C-terminal fragment (both 
atypical PrPres and PrPSc) or N-terminal fragment (only PrPSc). (from Makarava N et al., Am J Pathol 2016) 
 
After the formation of the first PrPSc, this latter can replicate independently of atypical 
PrPres. Supporting this model, in vitro generated amyloid fibrils from recombinant Syrian 
hamster PrP lacked any detectable PrPSc particles but were able to induce transmissible 
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prion disease in animals on serial passaging [234]. This mechanism proposed two main 
barriers between the injection of synthetic amyloids to the generation of authentic PrPSc. 
The first is attributed to a change in substrate from recombinant PrP to PrPC that possess 
GPI-anchor and N-linked glycans. These post-translational modifications may affect the 
ability of synthetic prions to transmit their misfolding to the PrPC. The second barrier is 
constituted by the low rate of deformed templating events that lead, in this model, to 
authentic PrPSc. High concentration of PrPC helped to cross the first barrier while the 
second barrier step seems to be independent from PrPC expression [235]. However, 
although the deformed templating events are not affected by PrPC expression, this 
mechanism is likely controlled by (i) the nature of the template, (ii) intrinsic rate of 
conformational errors in templating and (iii) the environment of prion replication. 
Particularly, cofactors present in the replication context not only shape the strain-specific 
structures [227] but may participate to the evolution process.  
However, atypical PrPres were described in synthetic hamster prion strains 
transmission but no mouse atypical PK-resistant PrP were detected suggesting that this 
mechanism might be not assumed as general model.  
 
1.12 Synthetic prions adaptation and selection  
Several studies conducted with the aim of assessing the stability of synthetic prion strains 
after serial passages in animals highlighted the ability of these preparations to change 
their pathological features similarly to that observed in inter-species transmission of prions. 
Accordingly, experimental findings suggest the possibility that different conformation of 
PrPSc might be originated by the same amyloid preparation. This heterogeneity can arise 
from: (i) the presence of a mixture of PrPSc conformations in the original amyloid 
preparations, (ii) stochastic events of conformational changes of PrPSc or (iii) infrequent 
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lack of fidelity during the prion replication process (deformed templating). Moreover, these 
hypotheses are in agreement with experimental observations that synthetic prions are able 
to: (i) change their pathological features trough in vivo passages and (ii) generate in 
animals two or more PrPSc conformations.  
Indeed, during serial animal passages within the same host, these preparations can 
undergo to a period of adaptation were their biochemical and neuropathological 
characteristics gradually change to reach stable pathological phenotype. An example of 
this adaptation was described for synthetic hamster prions [237]. Particularly, at least four 
serial passages in hamsters were required to stabilize SSLOW hamster prion strain 
characteristics including: incubation period, neuropathological features and tissue tropism. 
These changes in strain properties are frequently observed upon cross-species 
transmission and were attributed in large part to the sequence differences between PrPSc 
and host PrPC [174, 238]. The adaptation observed within the same host might involve a 
selection process of a PrPSc subpopulation that was best suited to replicate in a particular 
cellular environment (different tissues or different brain regions). Similarly to hamster 
synthetic strain evolution, changes in biochemical and physical properties of synthetic 
mouse prions were reported after serial passages in animals [214, 239, 240]. Particularly, 
a set of synthetic amyloids (generated under different chaotropic conditions) were 
inoculated in transgenic animal model overexpressing PrPC (Tg4053). On initial infection, 
the synthetic prion amyloids were able to induce different prion pathologies [214]. 
However, after serial passages, the neuropathological and biochemical features of each 
preparation gradually adapt and converge to a similar prion isolate characterized by 
analogous conformational stability and glycoform ratio [240]. This report demonstrated the 
ability of different amyloid preparation to change their physical and biochemical properties 
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on repeated passage within the same host and converge to one conformation by 
mechanism of selection and adaptation. 
Supporting the fact that synthetic prions might generate different prion isolates the 
transmission of MoSP1 [213] in transgenic mice expressing truncated PrPC (89-230) 
(Tg9949) and FVB mice revealed the presence of, at least, two distinct prion isolates 
named MoSP1(1) and MoSP1(2) [241, 242]. Additional studies on MoSP1(1) and 
MoSP1(2) revealed that these two strains were characterized by two different molecular 
mass of the unglycosylated PK-resistant PrP, 21kDa and 19kDa, respectively [239]. 
Particularly, when inoculated in cell cultures, MoSP1(1) and MoSP1(2) propagate with high 
fidelity. When both prion isolates were incubated together in the same cells, MoSP1(1) 
prevail on MoSP1(2) which slowly disappear. Most notably, the subsequent inoculation of 
cloned MoSP1(2) in animals overexpressing PrPC (Tg4053) resulted in the reappearance 
of small amounts of MoSP1(1). The model proposed for this phenomenon was based on 
the competitive selection. Thus, MoSP1(1) replicates faster than MoSP1(2), and this 
isolate might be more effective at interacting with PrPC (or other factors) competing with 
MoSP1(2) for the substrates required for its propagation [243, 244]. In that scenario, the 
faster replicating prion causes disease with shorter incubation time and induces the host 
death before the accumulation of the slower prion strain.  
These reports highlighted the ability of synthetic preparation to undergo to a 
process of selection and adaptation similar to that observed in cross-species transmission 
of prion strains. As shown for natural prions, the context of replication might play a role in 
selecting specific PrPSc conformations and actively participate to the adaptation process.  
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1.12.1 In vitro studies of synthetic prion selection and adaptation  
As for natural prions, in vitro amplification techniques like PMCA might be a fundamental 
tool for studying synthetic prion selection and adaptation mechanisms. The advantage of 
this technique is the possibility to alter in a precise manner the replication environment by 
adding or removing single components from the substrate of amplification such as RNA, 
lipids and other molecules in order to evaluate their effect on PrPSc replication. In 2012, 
Makarava and colleagues reported that modifications of PMCA conditions can lead to the 
amplification of different PrPSc using as source of infectious prions the brain of hamster 
injected with synthetic isolate [179]. Precisely, brain homogenates of hamster infected with 
LOTSS (LOw Toxicity Synthetic Strain) containing a mixture of atypical PrPres and PrPSc 
were used as seed for PMCA amplification with (i) normal hamster brain homogenate and 
(ii) partially de-glycosylated substrate (treated with PNGase F under non-denaturing 
conditions). This substrate treatment partially removes N-linked glycans leading to a 
shifting of the ratio of PrPC glycoforms from predominantly di-glycosylated to 
predominantly mono-glycosylated. After PMCA, the analysis of the amplified products 
revealed that standard PMCA was able to selectively amplify PrPSc while PMCA with 
partially de-glycosylated substrate (dgPMCA) preferentially amplified atypical PrPres. 
Notably, after only 4 rounds of standard PMCA, no signal from atypical PrPres were 
detected while dgPMCA amplify both PrPSc and atypical PrPres, but this latter preferentially. 
To test the infectious properties of standard PMCA amplified LOTSS, animal bioassays 
were performed. Surprisingly, in contrast to the animals inoculated with the original seed, 
hamsters injected with the PMCA amplified LOTSS developed clinical symptoms with 
100% attack rate. Notably, clinical manifestation of the disease was identical from that 
observed in animals after conventional in vivo passages of LOTSS suggesting that PMCA 
is able to mimic in vitro the process of in vivo strain evolution of prions. Another report 
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sustaining the role of the environment on prion selection and adaptation was published 
recently by Natalia Fernàndez-Borges and colleagues [245]. Particularly, they 
demonstrated that a synthetic prion conformation can be selected in PMCA from a mixed 
population using recombinant substrates in presence or absence of different cofactors like 
deaxtran, RNA and DNA. Notably, these selected synthetic prions were able to either 
replicate in PMCA (with brain homogenate of transgenic mice expressing bank vole PrP 
(TgVole) and bank vole 109I brain homogenates) or induce different prion pathologies 
when injected in animals.  
Taken together, these reports highlighted the fact that the alteration of the in vitro 
context of synthetic prion replication is able to modify their characteristics in a very similar 
manner to that of natural prions adaptation and selection.  
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AIM 
 
Aim of my PhD work was to evaluate the infectious, clinical neuropathological, biochemical 
and biophysical properties of a new synthetic prion isolate previously generated by our 
group and assess its ability to undergo to process of selection/adaptation in response to 
changes in the replication environment. For this purpose, we have performed serial 
transmission passages in wild-type mice and in vitro analysis with two innovative 
techniques named Protein Misfolding Cyclic Amplification (PMCA) and Real Time Quaking 
Induced Conversion (RT-QuIC) for deepening these phenomena. 
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CHAPTER II 
 
 
Materials and methods  
2.1 Intracerebral inoculation 
Six weeks-old Crl:CD1(ICR) (CD-1) mice (35–40 g) were anesthetized with 
Tribromoethanol (100μL/10g) i.p.-administered and 20µL of amyloid preparation or 2μl of 
each brain homogenate collected from terminally sick animals [246] and prepared in sterile 
phosphate buffer	 (10%, weight/volume) was stereotactically injected in the striatum (raw 
amyloids) or in the hippocampus (brain homogenate). All surgical procedures were 
performed under sterile conditions. Incubation time (I.T.) was calculated considering the 
days between inoculation and symptoms onset including: ataxia (uncoordinated 
movement), tail rigidity and kyphosis (hunched back). Survival time (S.T.) was calculated 
considering the days between the inoculation and the sacrifice of the animals at terminal 
stages of the disease. Brains were then harvested and half of them were collected for 
biochemical analysis and the other half was processed for histological evaluations. 
 
2.2 Neuropathological analysis 
Brains were fixed in Alcolin (Diapath), dehydrated and embedded in paraplast. Seven-
micrometer thick serial sections were stained with hematoxylin-eosin (H&E), thioflavin S, 
or immunostained with monoclonal antibodies to PrP (6H4, Prionics), and polyclonal 
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antibodies to glial fibrillary acidic protein (GFAP, Dako). Before PrP immunostaining the 
sections were pre-treated with Proteinase K (10 μg/mL, 5 min, room temperature, 
Invitrogen) and guanidine isothiocyanate (3M, 20 min, room temperature). Non-specific 
binding of the antibody was prevented using ARK kit (Dako). Immunoreactions were 
visualized using 3–3'-diaminobenzidine (DAB, Dako) as chromogen. Lesion profile was 
performed on H&E stained sections according to Fraser H. et al 1968 [155]. The areas 
evaluated were: 1. Dorsal medulla; 2. Cerebellar cortex; 3. Superior culliculus; 4. 
Hypothalamus; 5. Thalamus; 6. Hippocampus; 7. Septum; 8. Retrosplenial and adjacent 
motor cortex; 9. Cingulated and adjacent motor cortex. For each area, the severity of 
vacuolar lesions was graded 0 (no lesions) to 3 (extensive vacuolization) and the mean 
scores were calculated and then plotted with ±S.E.M. IHC images were acquired at 10X 
magnification with Nikon Eclipse E800 microscope equipped with Nikon digital camera 
DXM 1200 and Nikon ACT-1 (v2.63) acquisition software.  
 
2.3 Biochemical analysis  
Ten percent (weight/volume) brain homogenates were prepared in lysis buffer (NaCl 
100mM, EDTA 10mM, NP40 0,5%, Na-deoxycholate 0,5%, Tris-HCl pH 7.4 10mM). After 
a brief centrifugation (800 x g, 1 minute) 20μL of cleared lysate was digested with 50 
μg/mL of Proteinase K (1h, 37°C, 550rpm, Invitrogen). PK digestion was stopped by 
adding Loading buffer (Sample buffer 4X and DTT 10X, Thermo Scientific) and the 
samples were boiled (100°C, 10 minutes). The proteins were separated using 12% Bis-
Tris plus gels (Thermo Scientific) and transferred into polyvinylidene difluoride membranes 
(PVDF, Millipore). After non-fat dry milk blocking (1h, room temperature) the membrane 
was probed using anti-PrP antibodies (see List of antibodies) diluted in TBST and 0.05%-
	
	
70	
Tween-20 (Sigma). After incubation with Fab fragment anti-mouse IgG conjugated with 
horseradish peroxidase (HRP) (GE), blots were developed using the ECL Prime detection 
system (Amersham) and chemiluminescence was visualized using a G:BOX Chemi 
Syngene system. 
List of antibodies  
Antibody  Epitope (AA) 
6D11 93-109 
SAF-61 144-152 
SAF-84 160-170 
 
2.4 PNGase experiment 
Fifty μl of brain homogenates was digested with PK (100 μg/mL) for 1 hour at 37°C with 
shaking. PNGase digestion was performed following the instructions provided with the kit 
(PNGase F, P0704S, 15.000 units, New England Biolabs). Briefly, 4 μL of 10X 
glycoprotein denaturing buffer (provided with the kit) was added to the homogenate and 
the samples were boiled for 10 minutes at 100°C. Subsequently, 4 μL of G7 buffer 
(provided with kit), 4 μL of NP-40 (provided with kit), 4 μL of PNGase F and 4 μL of PBS 
were added to reach the final volume of 40 μL. Each sample was incubated 2 hours at 
37°C with shaking. The reaction was stopped by adding NuPAGE LDS sample buffer and 
Western blotting was performed. 
 
2.5 PMCA procedures 
PMCA was performed as previously described [194]. Briefly, as a substrate, were used 
brain homogenate from outbred CD-1 mice prepared in conversion buffer (PBS 1X 
containing 150 mM sodium chloride and 1% Triton X-100) with the addition of Complete 
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protease inhibitor cocktail (Roche). Ten μL of brain homogenate from infected mice was 
added to the substrate and transferred in 0.2mL PCR tubes, positioned on an adaptor 
placed on the plate holder of a micro-sonicator (Misonix, Model S3000) and subjected to 
96 cycles of PMCA. Each cycle (referred as PMCA round) consisted of 29’ and 40” sec of 
incubation at 37/40°C and 20” pulse of sonication set at potency of 260–270 Watt. After 
one round of PMCA, 10μl of the amplified material was diluted 10-folds into fresh substrate 
and a further PMCA rounds were performed. In order to increase the efficiency of 
amplification, 3 teflon beads were added to the reaction tube. To prevent samples cross-
contamination all the instruments and equipment were decontaminated using 2N sodium 
hydroxide (NaOH, Sigma) or 4M guanidine hydrochloride (GdnHCl, Sigma) and all the 
experiments were conducted with appropriate negative control.  
 
2.6 Blood processing 
Blood from symptomatic animals (140 days post inoculation) was collected from the tail in 
a 1.5 mL tube containing EDTA as anticoagulant. Four hundred µL of blood was treated 
with Ficol reagent to separate plasma from white cells and red cells. Plasma and white 
cells were collected and centrifuged at high speed (100.000 x g) for 1h at 4°C. Resulting 
pellets were washed with PBS, suspended in 100 µL of CD1 brain homogenate and 
subjected to PMCA. 
 
2.7 PK resistance assay 
Twenty μl of brain homogenate or PMCA products was digested with five increasing 
concentrations of PK enzyme (50, 100, 250, 500, 1000 µg/mL) for 1 hour at 37°C with 
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shaking. Samples were then immunoblotted with 6D11 antibody and densitometric 
analysis of resulting PK-resistant PrP band were performed.  
 
2.8 Conformational stability assay 
Fifty μl of brain homogenate or PMCA products was incubated with 450µL of guanidine 
hydrochloride (GdnHCl) solutions (Sigma) at different molar concentrations (0, 1.5, 3, 4.5 
and 6M) for 2h at 25°C with agitation (550rpm). Subsequently, an equal volume of 
Sarkosyl 20% was added to the samples and incubated for 10 minutes with gentle 
shaking. Samples were then centrifuged at 100 000 x g for 1h at 4°C. Pellets were washed 
with equal volume of PBS 1X (Gibco) and then centrifuged at 100 000 x g, 30’ at 4°C. The 
pellets were finally suspended in 50µL of Loading buffer and then processed for Western 
blot analysis (see Biochemical analysis for details). The membrane was incubated with 
anti-PrP 6D11 primary antibody (0.2 μg/mL, Covance). Densitometric analysis were 
performed. The concentration of GdnHCl required to unfold half of PrPSc ([GdnHCl]1/2) was 
then calculated with GrapPad software (v5.0) after non-linear regression curve fit 
(Boltzmann sigmoidal) of densitometric data. 
 
2.9 Recombinant full-length mouse PrP production and purification 
The pET-11a plasmid (Novagen) encoding for the full-length MoPrP(23–231) was kindly 
provided by Dr. J.R. Requena (University of Santiago de Compostela, Santiago de 
Compostela, Spain). The mouse construct was expressed in competent BL21 Rosetta2 
(DE3) cells Escherichia coli (Stratagene). Freshly transformed overnight culture was 
inoculated into Luria Bertani (LB) medium and 100 μg/mL ampicillin and 30 μg/mL 
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chloramphenicol. At 0.8 OD600 expression was induced with isopropyl b-D 
galactopyranoside (IPTG) to a final concentration of 1 mM. Cells were grown in a BioStat-
B plus fermentor (Sartorius). The cells were lysed by a homogenizer (PandaPLUS 2000) 
and the inclusion bodies were suspended in buffer containing 25 mM Tris-HCl, 5 mM 
EDTA, 0.8% TritonX100, pH 8, and then in bi-distilled water several times. Inclusion 
bodies containing MoPrP(23-231) were dissolved in 5 volumes of 8 M guanidine 
hydrochloride (GdnHCl), loaded onto pre-equilibrated HiLoad 26/60 Superdex 200-pg 
column, and eluted in 25 mM Tris–HCl (pH 8.0), 5 mM ethylenediaminetetraacetic acid, 
and 5 M GdnHCl at a flow/rate of 1.5 mL/min. Proteins refolding was performed by dialysis 
against refolding buffer [20 mM sodium acetate and 0.005% NaN3 (pH 5.5)] using a 
Spectrapor membrane (molecular weight, 10000Da). Purified protein was analyzed by 
SDS-polyacrylamide gel electrophoresis under reducing conditions and Western blot. 
 
2.10 RT-QuIC analysis 
RT-QuIC was performed as previously described with few modifications [247]. Briefly, 
recombinant full length mouse PrP (23-231) were filtered through a 100 kDa Nanosep 
centrifugal device (Pall Corporation) and mixed with the reaction buffer composed as 
follow: 0.2mg/mL recMoPrP(23-231), 10mM PBS, 130mM NaCl, 1mM EDTA, 0.002% SDS 
and 10µM ThT (all reagents from Sigma). 98 μL of the final reaction volume were 
dispensed in black 96-well optical flat bottom plate (Thermoscientific). To avoid 
contaminations, reaction mix was prepared in a prion-free laboratory and all the sample 
were analyzed in triplicate. After the addition of 2μL of brain homogenate or PMCA 
amplified products, the plate was sealed with a sealing film (Thermoscientific) and inserted 
into a FLUOstar OPTIMA microplate reader (BMG Labtech). The plate was shaken for 1 
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minute at 600 rpm (double orbital) and incubated for 1 minute at 42°C. A sample was 
considered positive if two out of three replicates crossed the threshold of 30% of the 
maximum ThT signal. Brain homogenate from terminally sick mice infected with RML prion 
strain (either subjected to PMCA or not) were used as control.   
 
2.11 Statistical analysis 
Means values are presented with their standard errors of the mean (S.E.M.). Log-rank test 
was used for the survival and incubation time analysis. Unpaired t-test, two tailed was 
used for p calculation. Statistical analysis and graphic representations were performed 
with Prism software (5.0v GraphPad). Densitometric analysis were performed using 
ImageJ software (1.48v). 
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CHAPTER III 
 
Results 
We previously generated different synthetic prion amyloid preparations using only 
recombinant full-length mouse PrP (recMoPrP) and common chemicals but systematically 
altering the conditions for their formation, including denaturant concentrations, pH and 
buffer composition. These results were published in 2015 in Plos Pathogens [246] and 
showed the ability of one of these amyloids (named amyloid #4) to induce the 
accumulation of PK resistant PrP in cells or to replicate in vitro by means of PMCA. For 
this reason, we decided to analyze the infectious properties of this amyloid in wild type 
mice. 
 
3.1 PMCA analysis of raw amyloid #4 and lysates from infected GT-1 and N2a cell lines 
First, we assessed the ability of amyloid #4 to propagate in vitro by means of PMCA using 
CD1 mouse brain homogenate as substrate for amplification. This preparation showed a 
PK resistant PrP signal after three rounds of PMCA (Fig. 3.1A). Subsequently, cell lysates 
collected from both N2a and GT1 cells infected with amyloid #4 were used as seed for 
PMCA reaction. The lysates of both cell lines were able to amplify in PMCA harboring a 
PK resistant signal after 3 rounds of amplification (Fig. 3.1B). Remarkably, the glycoform 
ratio of PK-resistant amplified product derived from amyloid #4 (either from raw amyloid or 
cell lysates) was characterized by a prevalence of the di-glycosylated band while the un-
glycosylated form migrated at around 20 kDa after PK digestion.  
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Fig. 3.1 PMCA analysis of amyloid #4 raw fibrils and cell lysates from infected cell lines. (A) Seeding 
ability of amyloid #4 by means of PMCA using CD1 brain homogenate as substrates. (B) PMCA amplification 
of GT1 and N2a cell lysates infected with amyloid #4.   
 
3.2 First in vivo transmission (FP) of amyloid #4  
Amyloid #4 preparation was intracerebrally inoculated in Crl:CD1(ICR) (CD-1) mice (n=7) 
(Fig. 3.2A) and a group of animals were injected with normal PBS as control. None of the 
animals of first passage (referred to as FP) injected with raw amyloids showed clinical 
signs of prion pathology and were culled at the end of their lifespan. Neuropathological 
and biochemical analysis confirmed the lack of PK-resistant PrP, absence of spongiform 
alteration, PrPSc deposition and astroglial activation (Fig. 3.2B and 3.2C). Immunoblots 
with different C-terminal anti PrP antibodies (SAF-84, residues 160–170; SAF-61 which 
recognize residues 144–152) was performed for checking the presence of atypical PrPres 
but no signals were detected.  
1 2 3 PMCA 
round
+ + +
1 2 3
+ + +
PMCA of N2a and GT1 cell
lysates infected with amyloid #4
GT1 cells N2a cells
1 2 3 PrP
C
+ + + - PK
PMCA of raw
amyloid #4
41 kDa
31 kDa
21 kDa
A B
41 kDa
31 kDa
21 kDa
PMCA 
round
6d11
	
	
77	
 
Fig. 3.2 Neuropathological analysis of first passage (FP) mouse brains. (A) Schematic diagram of first 
transmission passage (FP). (B) Western blot analysis of brains collected from FP animals with three 
monoclonal antibodies for PrP. PrPC indicates the cellular prion protein (C) Immunostaining for PK-resistant 
PrP (after PK treatment, 10µg/mL) and Glial Fibrillary Acidic Protein (GFAP) of hippocampus of FP1 and 
PBS injected mice. Images were acquired at 10X magnification.  
 
3.3 PMCA analysis of amyloid #4 injected animals and characterization of a new prion 
isolate 
Brain homogenates of animals injected with amyloid #4 (referred to as FP) were subjected 
to PMCA amplification and showed the presence in one mouse of a PrPSc signal after 
three rounds of PMCA (Fig. 3.3A). Notably, the amplified PrPSc (named PMCA-FP2) was 
characterized by the prevalence of the di-glycosylated isoform of PrP while no PrPSc was 
observed after the amplification of the other brain homogenates. PMCA-FP2 was 
biochemically analyzed and compared with known prion strains: (i) mouse adapted-vCJD 
(mo-vCJD), (ii) RML and (iii) ME7. With this experiment, we noticed that the un-
glycosylated band of PMCA-FP2 migrated at around 20 kDa, in an intermediate position 
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compared with the same band of RML or ME7 (migrating at 21kDa) and the one of mo-
vCJD (migrating at 19kDa) (Fig. 3.3B). Peptide N-glycosidase F (PNGase) digestion 
experiment, that remove all N-linked oligosaccharides from PrP, confirmed the molecular 
mass of the un-glycosylated band of PrP migrating at 20kDa. This observation also rules 
out the possible contamination of PMCA reactions with vCJD or BSE prion strains that are 
also characterized by the prevalence of the di-glycosylated form of PrPSc (Fig. 3.3C). 
 
Fig. 3.3 PMCA amplification and characterization of PMCA-FP2 prion isolate. (A) PMCA analysis of 
brain homogenates from FP animals using CD1 homogenate as substrate. Serial dilutions of RML prion 
strain were used as control. (B) Western blot comparison of PMCA-FP2 with RML, mo-vCJD and ME7 prions 
strains. (C) PNGase comparison of PMCA-FP2 with known prion strains. (Red arrow indicates the un-
glycosylated band of PMCA-FP2). 
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3.4 Second in vivo transmission (SP) of amyloid #4 
A second passage transmission (SP) was performed as schematically reported in Fig. 
3.4A. Particularly, two groups of CD1 mice (n=10) were intracerebrally injected with brain 
homogenate obtained either from the animal injected with amyloid #4 or PBS. No animals 
of the second passage developed prion disorders after 700 days post injection. 
Biochemical and neuropathological analysis confirmed the lack of PrPSc accumulation 
either in Western blot and immunohistochemical evaluation (Fig 3.4B and 3.4C). These 
brains were subjected to PMCA analysis and five rounds of amplification (R5) were 
performed. No PK-resistant PrP signal was detected suggesting (i) the absence of PrPSc in 
the brains of injected animals or (ii) the presence of a PrP conformation that was not able 
to replicate in vitro (Fig. 3.5).   
 
Fig. 3.4 Biochemical and immunohistochemical analysis of Second passage transmission (SP). (A) 
Schematic diagram of second passage transmission (SP). (B) Biochemical analysis of brain homogenates 
collected from SP animals. (C) Immunostaining for PK-resistant PrP (after PK treatment, 10µg/mL) and Glial 
Fibrillary Acidic Protein (GFAP) of hippocampus of SP1 animal and PBS injected mice. Images were 
acquired at 10X magnification.  
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Fig. 3.5 PMCA analysis of brain homogenates from SP. PMCA amplification (five rounds, R5) of brains 
collected from mice of the SP. RML serial dilutions were used as control of PMCA efficiency.  
 
3.5 First in vivo transmission (PP1) of PMCA amplified new prion isolate (PMCA-FP2) 
For verifying the infectivity of PMCA-FP2 amplified products we injected two groups of 10 
animals with either PMCA-FP2 or PMCA-PBS (Fig. 3.6A). All the animals injected with 
PMCA-FP2 developed prion disease with 100% attack rate. These animals (coded PP1) 
showed an incubation and survival time of 130 ± 4 and 160 ± 3.85 days (mean ± S.E.M.) 
respectively (Fig 3.6B). 
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Fig. 3.6 First transmission passage of PMCA-FP2 isolate. (A) Schematic diagram of the first transmission 
of PMCA-FP2 referred as PMCA Passage 1 (PP1). (B) Incubation and survival time analysis of PP1 mice 
injected with PMCA-FP2 and PMCA-PBS as control. 
 
3.6 Biochemical and PMCA analysis of mice injected with PMCA-FP2 prion isolate 
Brains and different tissues of terminally sick animals were collected and used for 
biochemical and immunohistochemical studies. PK-resistant PrP was detected in brains 
and spinal cord while in other tissues (spleen, eyes, kidney, muscle and liver) PrPSc were 
not detectable (Fig. 3.7A). Biochemical analysis showed the presence of a PK resistant 
PrP with di-glycosylated profile similar to that of the inoculum (PMCA-FP2) (Fig. 3.7A). 
PMCA analysis was carried out on eyes, spleens and blood samples. We detected 
resistant PrP amplification after one round in eyes and spleen tissues and after two rounds 
in blood (Fig. 3.7B) Particularly, blood samples from symptomatic animals were collected 
after 140 days post injection. Using the RML as positive control for PMCA, we could 
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estimate that the concentration of infectious prion circulating in blood is similar to that of a 
10-10 dilution of brain homogenate. Notably, all the PMCA amplified products maintained 
the predominance of the di-glycosylated isoform of PrP as observed in brains of the 
animals (Fig. 3.7B). 
 
Fig. 3.7 Biochemical and PMCA analysis of tissues collected from PP1 animals. (A) PK-digestion and 
Western blot analysis of brains, spinal cords, spleens and eyes of PP1 mice. (B) PMCA amplification of 
spleens, eyes and blood of PP1 animals. Dilutions of RML prion strain were used as internal control.  
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amplified products (after 2 rounds) that showed similar resistance to proteolytic treatment 
with PK indicating that the biochemical characteristics of the prion isolate after PMCA were 
faithfully retained (Fig. 3.8B). 
 
Fig. 3.8 PMCA analysis and PK-resistance assay of PP1 animals. (A) In vitro amplification of PP1 brains 
by means of PMCA using CD1 brain homogenate as substrate. (B) PK resistance assay and western blot 
analysis before and after PP1 PMCA amplification. Errors bars represent the standard error of the mean 
(S.E.M). 
 
3.7 Neuropathological analysis of mice injected with PMCA-FP2 prion isolate. 
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prominent gliosis in PMCA-FP2 injected animals. The lesion profile analysis revealed 
severe spongiosis in the hippocampus and dorsa medulla while less vacuolization was 
found in the rest of the brain, including cerebral cortex and thalamus (Fig. 3.9C).  
 
Fig. 3.9 Neuropathological and immunohistochemical characterization of PP1 animals. (A) 
Immunostaining for PK-resistant PrP, GFAP and hematoxylin and eosin staining of hippocampus, frontal 
cortex and cerebellum of PP1-1 animal and PBS injected mice. (B) Thioflavin-S (ThS) staining of PP1-1 
frontal cortex. Images were acquired at 10X magnification. (C) Lesion profile of PP1 and PBS injected 
animals. The mean score for each area were reported in the graph. 1. Dorsal medulla; 2. Cerebellar cortex; 
3. Superior culliculus; 4. Hypothalamus; 5. Thalamus; 6. Hippocampus; 7. Septum; 8. Retrosplenial and 
adjacent motor cortex; 9. Cingulated and adjacent motor cortex. Errors bars represent the standard error of 
the mean (S.E.M). 
 
3.8 Second in vivo transmission (PP2) of PMCA amplified prion isolate PMCA-FP2. 
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was then performed (schematically represented in Fig. 3.10A). All injected mice 
succumbed to prion pathology with 100% attack rate but two different phenotypes of the 
disease were observed. The first was characterized by fast incubation and short survival 
time, respectively of 130.90 ± 0.86 and 164.66 ± 2.81 days post injection (mean±S.E.M.) 
(Profile 1, black lines) (Fig. 3.10B). These animals showed constant decreasing of body 
weight during the course of the disease (Fig. 3.10C). By contrast, the other group of PP2 
animals (Profile 2, red lines) was characterized by statistically significant longer disease 
duration with respect to that of Profile 1 (incubation time of 162 ± 6.18 and survival time of 
227.50 ± 6.33 days post injection, (mean±S.E.M.)) (Fig. 3.10B). A constant increasing of 
the body weight during the symptomatic phases that decreased only in the final stages of 
the disease was observed in this animal group (Fig. 3.10C).  
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Fig. 3.10 Second transmission passage (PMCA passage 2, PP2) of PMCA-FP2 isolate. (A) Schematic 
diagram of PMCA-FP2 second in vivo transmission. (B) Incubation and survival analysis of PP2 animals 
(Profile-1 (PP2-M) black lines, Profile-2 (PP2-D) red lines) (Log-rank test, * p<0.05, ** p<0.01, *** p<0.001) 
(C) Body weight assessment of PP2 animals during the symptomatic stage of the disease.  Errors bars 
represent the standard error of the mean (S.E.M). 
 
3.9 Biochemical analysis of mice from second in vivo transmission of PMCA-FP2  
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M had a strong PrPSc signal but surprisingly the biochemical profile of this protein was 
different from that present in the brain. It was indeed characterized by a prevalence of the 
di-glycosylated band (Fig. 3.11). These observations indicate that PrP present in our 
inoculum was able to adopt two alternative conformations, named PP2-M and PP2-D, 
associated with different disease phenotypes.  
 
Fig. 3.11 Biochemical analysis of different tissues collected from PP2 mice. PK-digestion and Western 
blot analysis of brains, eyes and spleens of PP2 animals.  
 
3.10 Neuropathological analysis of mice from second in vivo transmission of PMCA-FP2.  
Immunohistochemical analysis confirmed that PP2-M and PP2-D produced different 
neuropathological alterations in the brain of injected animals. In particular, after treatment 
with PK, samples were immunostained with anti-PrP antibody (6H4) and revealed that 
mice with PP2-M had a synaptic and widespread deposition of prion throughout the brain. 
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On the contrary, mice with PP2-D showed prion deposition mainly confined to the stratum 
lacunosum moleculare of the hippocampus and to the deep layers of the cortex with the 
presence of few plaque-like deposits, which did not possess the tintorial properties of 
amyloid (Fig. 3.12A and 3.12B). Few depositions of PrPSc was observed in the cerebellar 
cortex of both group of animals. Glial activation was found to correlate with PrPSc 
deposition in frontal cortex and hippocampus (either in terms of localization or intensity of 
the signal), which was different between both groups of animals (Fig 3.12A). 
 
Fig. 3.12 Neuropathological and immunohistochemical analysis of animals with PP2-M and PP2-D. 
(A) Immunostaining for PK-resistant PrP, Glial fibrillary acidic protein (GFAP) and hematoxylin and eosin 
staining of frontal cortex, hippocampus, and cerebellum of mice with PP2-M and PP2-D. (B) Thioflavin-S 
(ThS) staining of frontal cortex of mice with PP2-M and PP2-D. Images were acquired at 10X magnification.  
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hippocampus are mostly affected in PP2-D animals, while thalamus and cingulated cortex 
are mostly involved in PP2-M animals (Fig 3.13B).  
 
Fig. 3.13 Lesion profile of PP2 animals. (A) Lesion profile of animals with PP2-M and PP2-D. Brain areas 
correspond to: 1. Dorsal medulla; 2. Cerebellar cortex; 3. Superior culliculus; 4. Hypothalamus; 5. Thalamus; 
6. Hippocampus; 7. Septum; 8. Retrosplenial and adjacent motor cortex; 9. Cingulated and adjacent motor 
cortex (* p<0.05, ** p<0.01, *** p<0.001). Errors bars represent the standard error of the mean (S.E.M). (B) 
Hematoxylin and eosin stained sections of most representative brain areas of PP2. Images with solid box 
were acquired at 40X magnification while image with dotted box were acquire at 20X magnification.  
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isolates. 
To better characterize the biochemical and biophysical properties of PP2-M and PP2-D we 
performed (i) PK-resistance and (ii) conformational stability assays. The samples were 
then analyzed by means of Western blotting and densitometric analysis. The results were 
plotted in a graph and revealed that PP2-D appeared to be more resistant to PK digestion 
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and 1000 µg/mL concentration of PK. Conformational stability assay revealed that PP2-M 
is more stable against to GdnHCl treatment with respect to PP2-D. Especially, significant 
differences were observed at 3M concentration of chaotropic agent (Fig. 3.14B). Thus, 
PP2-M is less resistant to PK digestion but more stable against guanidine treatment than 
PP2-D which is instead more resistant to PK but less stable in GdnHCl. We have finally 
determined the concentration of GdnHCl required to unfold half of PrPSc ([GdnHCl1/2]). As 
reported in the graph (Fig. 3.14C) we found statistically significant differences between the 
[GdnHCl1/2] of PP2-M (3.344±0.1663) and PP2-D (1.904±0.2695) (mean(M)±S.E.M.). 
 
Fig. 3.14 Biochemical and biophysical assessment of PP2-M and PP2-D prion isolates. (A) PK-
resistance assay and (B) Conformational stability assay of animals with PP2-M (black lines) and PP2-D (red 
lines). (C) [Gdn-HCl]1/2 of PP2-M and PP2-D isolates. (* p<0.05, ** p<0.01, *** p<0.001). Errors bars 
represent the standard error of the mean (S.E.M). 
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3.12 PMCA analysis of in vivo generated prion isolates. 
PP2-M and PP2-D tissues (brains, eyes and spleens) were analyzed by means of PMCA 
to assess their amplification’s efficiency and their ability to retain the biochemical features 
of the original inoculum. Results confirmed that both isolates were able to efficiently 
amplify from all the tissues analyzed but, regardless of the inoculum (PP2-M or PP2-D) the 
final products of amplification were characterized by a PrPSc with a prevalence of the 
diglycosylated band (Fig 3.15A). Notably, despite PrPSc was not detectable in PP2-D 
spleens, after 1 round of PMCA a PK-resistant signal was detected. These results 
indicates that the biochemical profile of PP2-D was maintained while that of PP2-M was 
lost during the amplification process and new biochemical features were acquired. To 
exclude any technical bias, we tested the fidelity of PMCA amplification by subjecting 
mouse adapted-vCJD (mo-vCJD) and RML prion strains to several rounds of PMCA. mo-
vCJD is indeed characterized by the prevalence of di-glycosylated PrP isoform, while RML 
by the mono-glycosylated one. After amplification, the biochemical characteristics of both 
prion strains were retained, thus suggesting that PMCA is able to amplify different prion 
strains with high fidelity (Fig. 3.15B). For this reason, the amplification products of PP2-M 
suggest that a process of adaptation or selection might have occurred and gave rise to the 
formation of an isolate with different biochemical features.  
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Fig. 3.15 PMCA analysis of PP2-M and PP2-D isolates. (A) PMCA amplification of PP2-M and PP2-D 
isolates from brains, eyes and spleens of PP2 animals. (B) Internal control of PMCA amplification fidelity with 
mo-vCJD and RML prion strains.  
 
We then performed PMCA analysis of PP2-M and PP2-D with the aim of evaluating if PP2-
M and PP2-D are “pure” isolates or a mixture of different PrPSc. For these reasons, we 
performed serial dilutions (from 10-3 to 10-12 dilution of brain homogenate) of both PP2-M 
and PP2-D isolates in PMCA substrate and subjected these samples to amplification. With 
this experiment, we give the opportunity to under-represented conformation of PrPSc 
eventually present in our isolates to replicate in vitro. Both PP2-M and PP2-D, 
independently from the dilution performed showed di-glycosylated amplified product after 
one and two rounds of amplification (Fig. 3.16). These data suggest that the PMCA 
context of replication might be able to selectively amplify a PrP isoform characterized by 
di-glycosylated profile.  
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Fig 3.16 PMCA amplification of serial dilution of PP2-M and PP2-D isolates. PMCA amplification of 
serially diluted PP2-M and PP2-D (from 10-3 to 10-12 dilution of brain homogenates) using CD1 brain 
homogenate as substrate. 
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comparison with the original isolates. 
Since this biochemical profile is similar to that of PP2-D we wondered whether PMCA 
might have indeed preferentially amplified PP2-D, thus demonstrating that it might coexist 
with PP2-M, or was able to sustain the replication of a different PrPSc isoform. For these 
reasons, PMCA products (either from PP2-M or PP2-D) were subjected to biochemical 
and biophysical analysis, including (i) PK resistance assay (Fig. 3.17A) and (ii) 
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generate a unique isolate, termed PP2-PMCA. This isolate was characterized by the 
presence of a PrPSc with a predominance of the di-glycosylated band. Surprisingly, PK 
resistance and GdnHCl assays showed that PP2-PMCA (Fig. 3.17 solid lines) possessed 
biophysical features quite different from those of either PP2-M or PP2-D (Fig. 3.17 dotted 
lines). In particular, PP2-PMCA was much more resistant to PK and more stable in 
GdnHCl than PP2-M and PP2-D (Fig. 3.17A and B).  
 
Fig. 3.17 Biophysical characterization of PP2-PMCA isolate. (A) PK-resistance assay and (B) 
Conformational stability assays of PMCA-PP2 amplified isolates (PP2-M (PMCA) and PP2-D (PMCA))                      
(* p<0.05, ** p<0.01, *** p<0.001). Errors bars represent the standard error of the mean (S.E.M). 
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and fluorescence intensity (Fig. 3.18A). By further analyzing the slope, that numerically 
describe the steepness of the kinetic curves, we have found that the slope of PP2-M was 
smaller than that of PP2-D (Fig. 3.18B) thus further sustaining the fact that both isolates 
are different from each other. The slope of PP2-PMCA acquired an intermediate value 
between PP2-M and PP2-D but still statistically different from either of them. These 
findings suggested that also PP2-PMCA seems to be a different isolate characterized by 
its own seeding activity. As control, we analyzed the seeding activity of RML brain 
homogenate either before or after PMCA amplification. In this case, the slopes of the 
curves were similar and not statistically significant differences were found thus confirming 
that, likely, PMCA amplified this strain with high fidelity (Fig.3.18C). 
 
Fig. 3.18 RT-QuIC assay of PP2-M and PP2-D isolates. (A) Representative kinetic curves of recombinant 
mouse PrP (23-231) seeded with PP2-M, PP2-D, PP2-PMCA, RML and RML-PMCA. (B) Analysis of the 
slope of PP2-M and PP2-D and PP2-PMCA aggregation kinetic curves. (* p<0.05, ** p<0.01) (C) Analysis of 
the slope of RML and RML-PMCA aggregation kinetic curves. Errors bars represent the standard error of the 
mean (S.E.M). 
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CHAPTER IV 
 
Discussion 
In recent years, a body of evidence demonstrated that under specific biochemical 
conditions, recombinant PrPC can be misfolded in vitro into amyloid structures which were 
able to cause illness and produced pathological features in animals similar to that 
observed in natural occurring prion diseases. The advent of synthetic prions permitted the 
study of different aspects of prion biology including the basis of prion replication and the 
phenomenon of prion adaptation and selection with highly pure preparations instead of 
natural derived prion strains. We have previously shown the ability of a synthetic amyloid 
(amyloid #4) to induce accumulation of PrPSc in both N2a and GT-1 cell lines [246]. The 
synthetic amyloid and the lysates from infected cell lines were analyzed by means of 
PMCA for assessing the ability of the synthetic prion to propagate in vitro. In both cases, 
we were able to detect a PrPSc signal after three rounds of PMCA characterized by the 
predominance of the di-glycosylated band of PrP. When injected in wild-type animals, the 
synthetic prion did not produce any evident prion pathology in the (i) first (FP) and (ii) 
second passage (SP). This phenomenon could have several explanations. For example, 
Makarava et al. [234] reported that there is a period of time where the amyloid structure is 
converted to an intermediate and atypical form of PrPres (deformed templating) before 
producing the classical PrPSc which is able to trigger evident pathological changes in mice. 
Since the atypical PrPres is characterized by a short PK-resistant core, we have digested 
the brain of amyloid #4 injected mice with different concentrations of PK and used 
antibodies which recognize more C-terminal fragments of PrP (SAF-84, residues 160–170; 
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SAF-61 antibody which recognize residues 144–152). Even with these modifications we 
could never detect any typical or atypical PK resistant PrP. Another explanation for the 
lack of pathological changes in mice injected with amyloid #4 could be attributable to the 
small amount of infectious material used to challenge the animals. In this case, the amount 
of amyloids could not have been sufficient to misfold enough PrPC and induce disease.  
We have subjected the CNS of the FP animals to PMCA analysis and we detected the 
presence of a PK-resistant PrP in 1 out of 7 CNS analyzed after 3 rounds of amplification. 
Notably, the amplified product maintained the predominance of di-glycosylated PrP 
isoform previously observed from the amplification of the raw synthetic prion and was 
characterized by the presence of an un-glycosylated band migrating at around 20kDa. 
This product (referred as PMCA-FP2), was challenged in mice for assessing its 
infectious properties. PMCA-FP2 isolate was able to induce highly aggressive prion 
pathology in animals with 100% attack rate. Biochemical analysis confirmed the ability of 
the amplified product to induce the formation of PrPSc characterized by the same 
biochemical features of the inoculum (predominance of the di-glycosylated form of the 
protein). PrPSc were detected also in blood of symptomatic animals confirming the 
aggressiveness of the new prion isolate. Neuropathologically, PMCA-FP2 was able to 
induce spongiform lesions with distinct distribution with respect to standard mouse prion 
strains.  
Brain homogenate of these animals where used to perform a second transmission 
experiment (PP2). All the animals succumbed to prion disease but in their brains we could 
detect the presence of two different prion isolates. In the 80% of the cases the PrPSc was 
characterized by a predominance of the mono-glycosylated band (PP2-M), while in the 
other 20% it was characterized by a predominance of the di-glycosylated isoform (PP2-D). 
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These differences in the biochemical profiles were associated to different (i) clinical 
manifestations of the disease (including incubation time, survival time and body weight 
changes) (ii) neuropathological changes (deposition of PrPSc and spongiform alterations) 
(iii) biochemical and biophysical features of both PrPSc (PK-resistance assay and GdnHCl 
conformational stability assays) and different seeding activity when assessed by means of 
RT-QuIC. In particular, PP2-M induced a faster disease progression, was less resistant to 
PK digestion and showed higher stability to GdnHCl denaturation compared to PP2-D.  
Considering data from the literature, the conformational stability of prion strains 
appear closely related to the clinical course of the disease [248]. For instance, as reported 
for hyper (HY) and drowsy (DY) in hamsters, PrPSc associated to HY is characterized by 
high conformational stability and induce faster disease progression while that associated 
to DY possesses low conformational stability and is responsible for longer disease 
duration. This correlation was also found in our synthetic prion isolates, where PP2-M is 
more stable and it induced shorter disease duration than PP2-D, which in turn is less 
stable and leads to longer disease duration. As reported by previous studies [241, 248, 
249] the inverse relationship between PrPSc stability and disease duration cannot be 
assumed as general model, particularly in the case of synthetically derived prion strains. 
Recent data [250] suggest that this characteristic might be influenced by (i) recPrP primary 
sequence of synthetic prions and (ii) the animal model used for bioassays. Altogether 
these data support the hypothesis that the serial in vivo passages were able to generate 
two different isolates that spontaneously arose from our original inoculum due to 
mechanisms of selection or adaptation that are not understood yet. It seems that the 
context of prion replication plays an important role in guiding these phenomena.  
These insights suggest the intrinsically heterogeneous composition of prion strains 
and their ability to adapt in response to environment pressure in agreement to the 
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Darwinian evolution theory [185]. Two main hypotheses were proposed as possible 
mechanism: the “cloud” hypothesis and the adaptation mechanism. The cloud hypothesis 
infers that the prion population is composed of a multitude of conformational variants. 
Changing the replication environment allows the most efficiently replicating variant to 
becomes the predominant component of the population which then constitutes a distinct 
sub-strain [185]. On the contrary, the adaptation mechanism consists of a long clinically 
silent stage which is accompanied by a slow modification of the biophysical and 
neuropathological properties of PrPSc. The long adaptation period of synthetic prion when 
injected in animals is attributed to structural changes of PrP conformation that, in a 
mechanism named “deformed templating”, lead to a generation of an authentic PrPSc. The 
deformed templating mechanism proposed that the first product of PrPC misfolding 
triggered by recombinant amyloids generate a self-replicating state of PrP named atypical 
PrPSc. After several serials passages the atypical PrPSc gave rise to a PrPSc with specific 
biochemical and neuropathological characteristics [187, 236]. 
We are not able to determine whether the generation of two isolates is mainly due 
to either a process of selection or adaptation. Indeed, the original inoculum, although 
produced using highly pure source of recombinant PrP and strictly controlled biochemical 
conditions, might have produced different isolates of misfolded PrP. When passaged in 
mice, only two of these isolates seemed to replicate with higher efficiency compared to 
others, which induced different pathologies. It is reasonable to argue that, although not 
detectable, the other isolates might still be present and able to replicate with lower 
efficiency. The amplification of the two isolates might have also been favored by the 
characteristics of the outbred animals utilized in the in vivo experiments. Recent evidence 
shows that minimal variations in the genetic background of the host animals can 
significantly influence the biochemical features of PrPSc [251]. Therefore, differences in the 
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genetic background of CD-1 animals might have favored the replication of PP2-M or      
PP2-D while interfering with the replication of other isolates. However, differences in the 
level of PrPC expression were shown to play a role in driving the glycosylation pattern of 
PrPSc [252]. Considering that PP2-M and PP2-D differentially accumulated in distinct brain 
regions, we might speculate that (i) such areas might be characterized by the presence of 
slightly different levels of PrPC that can significantly influence the glycosylation of our 
isolates or (ii) PP2-M and PP2-D might preferentially replicate in different cell types such 
as neurons or astrocytes. Furthermore, the ubiquitin-proteasome system (UPS) and 
lysosomal systems may contribute to the prevalent selection of some prion isolates more 
resistant to proteolytic degradation [253, 254].  Compelling evidence indicates that prions 
can change their abnormal conformation in response to events unrelated to changes of the 
environment of replication by spontaneous structural modifications of the PrPSc [167]. 
These phenomena might also explain the appearance of new prion strains after inter-
species prion transmission. In this scenario, the pressure exerted either by the new 
environment or by differences in PrPC sequence might force the protein to misfold with 
different conformation.  
Through PMCA analysis of PP2-M and PP2-D we observed the generation of an 
amplified product (PP2-PMCA), which was not found in vivo and showed different 
biophysical properties from those of PP2-M and PP2-D. We do not know the precise 
mechanisms which led to the preferential replication of PP2-PMCA but a fundamental 
aspect that we need to consider is that PMCA provides solely the permissive environment 
for prion replication, without the presence of any cellular interactions or compartments 
(Endosomes with acidic pH). Acidic pH of endosomal compartments have been suggested 
as relevant for PrPC/PrPSc conversion [255] while the pH of the PMCA reaction is neutral, 
homogenous and stable. Thus, these conditions might have favored the replication of a 
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third isolate different from PP2-M and PP2-D. Indeed, PMCA exposes the samples to high 
power of cyclical sonication and might contribute in changing the biochemical and 
biophysical features of the final amplified product.  
Likely, the context of PMCA amplification can impose an evolutionary pressure that 
may select the isolate able to better replicate in this environment. Therefore, we can infer 
that the PrPSc conformation amplified by PMCA might have been present in all the animal 
brains but was not able to replicate in vivo.  
In conclusion, our data indicate that putative infectious materials can be generated 
in vitro, under controlled and well-defined biophysical and biochemical conditions using 
solely recombinant PrP and some simple chemicals, without employing prion infected 
brain homogenate or purified PrPSc. We observed that the amyloid #4 maintained the 
same biochemical profile when amplified from (i) the synthetic preparation or (ii) the 
infected cell lysates and finally (iii) from the brain of infected mouse. Nevertheless, after 
PMCA amplification, this newly generated synthetic prion was found to induce a severe 
prion pathology when injected in mice. 
Notably, that synthetic prion amyloids are able to change their biochemical and 
infectious properties in response to (i) repetitive animal passages and (ii) changes in the 
context of replication through phenomena of prion adaptation and selection. As observed 
for natural-derived prion strains, also synthetic prion strains may undergo a process of 
adaptation after animal passages. These data show that either the environment or other 
factors contribute to (i) altering the conformation of PrP giving rise to new ones whose 
replication is more efficient in the modified environment or (ii) favoring the replication of 
few prion isolates over others that might coexist in the same strain. 
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The two main mechanisms proposed for prion “evolution”, the cloud hypothesis and 
the deformed templating (detailed in Introduction) might explain the behavior of our 
synthetic prion but we are not able to determine whether the generation of different PrPSc 
conformations is mainly due to either a process of selection of pre-existing PrPSc or an 
adaptation of PrPSc isolate through animal passages. These insights suggest the 
intrinsically heterogeneous composition of prion strains and their ability to adapt in 
response to environment pressure. 
Events of prions selection were already observed after pharmacological treatment 
of cell cultures [185] or infected animals [188, 189] where the generation of drug-resistant 
variants of the original PrP strain were described. This because the pharmacological 
treatments were able to modify the environment thus inhibiting the replication of specific 
strains while selecting drug-resistant conformations that can replicate in the new 
environment and sustain the pathological process. This might explain why there are still no 
effective therapies for these devastating disorders.  
The possibility to modulate the replication environment by exploiting innovative 
techniques such as PMCA and RT-QuIC would help to an understanding of the 
mechanism of prion selection and adaptation in response to cellular environmental 
changes and identify novel pharmacological target for anti-prion compound.       
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